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1. General Part 
1.1. Introduction 
Today cancer is accountable for about 25% of deaths in developing countries and for 
15% of all deaths worldwide and therefore, cancer is one of the leading health problems 
in our society.1 According to statistics of the International Agency Research on Cancer 
(IARC) of the World Health Organization (WHO) 12.4 million incident cases of cancer 
were expected in 2008.2 These impressive statistical data suggest that anti-tumor 
therapy is a very important research field today. 
Cancer therapy includes surgery, radiotherapy and systematic chemotherapy. 
Chemotherapeutic drugs, so called cytostatic or cytotoxic agents, prevent cell division of 
malignant cancer cells and as a result lead to the death of these cells. 
Chemotherapeutics developed in the past 50 years have different points of action in 
human cells, show different biological effects, and have diverse chemical structures.1 
One very important class of anti-tumor agents are natural products, so called 
antineoplastic agents, which combat the development of neoplasms. Structurally 
different natural products are in clinical use, for example the vinca alkaloids vinblastine 
(1) and vincristine (2), or taxol (3) (Figure 1) and the epothilones.3 
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Figure 1: Antineoplastic agents in clinical use 
In 1982 Pettit and co-workers isolated the cis-stilbene derivative combretastatin A-4 
(CA-4, 4, Figure 2) from the bark of the African willow tree Combretum caffrum, which 
was found to be biologically most potent.4-6 
   2 
 
Figure 2: Structure of Combretastatin A-4 
The natural product shows cytotoxicity against a wide range of human cell lines, 
including multi drug resistant (MDR) cell lines. CA-4 binds to tubulin at the colchicin 
binding-site and inhibits microtubule-polymerization which leads to cell cycle arrest at 
the transition from meta- to anaphase and finally to apoptotic cell death.  
In the past years several structure-activity relationship (SAR) studies were carried out 
and they all came to the same result, that CA-4 is only active in cis-form. Furthermore, 
the oxygenation pattern on the two aromatic ring systems is necessary for biological 
activity. Due to isomerization to the thermodynamically more stable trans-isomer and 
high lipophilicity, CA-4 shows low in vivo activity.7,8 
Structural modifications are possible and several derivatives were synthesized, which 
show better in vivo activities than the natural product. Some derivatives used in clinical 
studies are shown below (5-8, Figure 3).9-12 
 
Figure 3: Derivatives in clinical studies 
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1.2. Aim of the synthetic work 
The aim of our synthetic work is to increase the biological activity of the natural product 
CA-4 by modifying the cis-double bond. The incorporation of three- and four-membered 
carbocycles (9, 10, Figure 4) prevents the in vivo isomerization of the cis-stilbene 
derivative to the thermodynamically more stable trans-isomer. 
 
Figure 4: Synthesis of CA-4 derivatives 
In the experimental part the syntheses of several biologically interesting cyclopropane 
derivatives via cyclopropanation with diazomethane are described in detail. Initial 
studies towards the synthesis of corresponding cyclobutane derivatives were carried 
out. However the approaches described herein could not be completed to date. Two 
later described approaches via [2+2]-cycloaddition and over the squaric acid 
cyclobutane building block did not come to an end. 
1.3. Isolation 
The Combretaceae plant family comprehends 20 genera and more than 600 species 
which are growing in tropical and subtropical regions as shrubs and trees. The genus 
Combretum was known centuries ago for its medicinal properties and was used in the 
primitive medical practice in Africa and India. In 1979 Pettit and co-workers started an 
investigation on the cytotoxic effects of compounds isolated from the bark of the African 
willow tree Combretum caffrum which are active against murine P-388 lymphocytic 
leukaemia.13,14 In the following years natural compounds known as combretastatins 
were isolated from the bark of this African willow tree.4,6,13-17 
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Figure 5: Combretastatin family 
Figure 5 shows the members of the combretastatin family (4, 11-20). All 
combretastatins except Combretastatin (11), A-6 (16), D-1 (19) and D-2 (20) have a cis-
stilbene core structure. They show different substitution patterns of phenol- and 
methoxy-functionalities on the two aromatic ring systems which are connected over a 
two-carbon-bridge, with or without a double bond. Combretastatin D-1 and D-2 possess 
more complex structures; these are 17-membered macrocyclic lactones. 
The combretastatins were all isolated following the same procedure. The isolation of 
CA-4, CA-5 and CA-6 is discussed below. First 77 kg of dry bark of Combretum caffrum 
was extracted with a methylene chloride-methanol mixture. This extraction was followed 
by a solvent partition sequence and a gel filtration of the methylene chloride extract 
through Sephadex LH-20. Subsequent column chromatography and further purification 
by HPLC gave a seemingly pure fraction. However, the data of 1H- and 13C-NMR 
pointed out that this fraction was a mixture of the three above-named stilbene 
derivatives. This mixed fraction was treated with TBS-Cl to get the silyl-ethers of the 
three components which could be separated by preparative thin layer 
chromatography.4,15 
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The combretastatins all show antimitotic activity. Their presence in a cancer cell blocks 
the microtubule polymerization dynamics by binding on the colchicine binding site. 
Some members of this natural product family also show antivascular effects in tumor 
cells. These compounds are of additional interest because of their structural simplicity, 
and therefore can be easily prepared by synthetic means. CA-4 shows the most potent 
antitubulin effects. If CA-4 is used as an inhibitor of colchicine in an equimolar ratio, 
binding of colchicin at its binding site is inhibited by over 95% by CA-4.6 
1.4. Structural related compounds 
1.4.1. Phenanthrenes 
 
Figure 6: Phenanthrene core structure 
Phenanthrenes and CA-4 show the same core-structure. Two aromatic ring systems are 
connected over a two-carbon-bridge. The only difference is that in phenanthrenes the 
two aromatic rings are stabilized over a single bond on ortho-position of the connecting 
bridge (Figure 6, structural motif 1) 
The phenanthrenes isolated so far can be divided into three groups: mono- di- and 
triphenathrenes. Monophenathrenes can be subdivided according to different 
substitution patterns on the ring systems. Because of different connectivity of the 
phenanthrene subunits, diphenanthrenes can also be additionally classified. Up to this 
date only one isolated triphenanthrene is described in literature. Compounds without a 
double bond on the connecting carbon bridge are called dihydrophenanthrenes. Figure 
7 shows only a few examples of known phenanthrenes and dihydrophenanthrenes (21-
29). 
   6 
 
Figure 7: Examples of isolated phenanthrenes 
In the past years a large number of phenanthrenes were isolated from higher plants, 
almost all from the Orchidaceae plant family and several dihydrophenanthrenes were 
also found in the African willow tree Combretum caffrum, (30-32, Figure 8). Their 
cytotoxicity was tested on murine P388 lymphocytic leukaemia cell lines representing 
IC50 values of an average of 2 μg/mL. 
 
Figure 8: Phenanthrenes isolated form Combretum caffrum 
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Phenanthrens show different biological activities: anticancer effects, antimicrobial 
effects, spasmolytic effects, antiallergic- and anti-inflammatory activities.18 
1.4.2. Colchicine 
 
Figure 9: Colchicine 
Colchicine (33, Figure 9) was isolated first in 1820 from the poisonous plant meadow 
saffron (Colchicum autumnale L.), also known as autumn crocus, by Pelletier and 
Caventou. The poisonous plant was known for more than 2000 years and was used in 
naturopathy in the treatment of acute gout. Up to present colchicine is applied in the 
therapy of gout and familial Mediterranean fever, but its high toxicity reduces its use in 
other therapies.19 
Colchicine acts as an antimitotic agent and binds to tubulin at the colchicine binding 
site. More precisely it interacts with the spindle microtubules during cell division. This 
interaction causes the destruction of the tubulin/microtubule polymerization dynamics 
and as a consequence mitosis is arrested in metaphase. This point of action in a living 
cell is a very interesting approach in cancer therapy because such compounds can be 
used for the selective damage of rapidly proliferating cancer cells.20 
As mentioned above, colchicine cannot be used as a chemotherapeutic agent because 
of the high toxicity. In the past years several derivatives were synthesized with the 
fundamental goal to increase the biological activity of the natural product.21 
Several QSAR (quantitative structure-activity relationship) studies were carried out but 
the toxicity could only scarcely be minimized. Thiocolchicine (34) and demecolcine (35), 
two colchicine derivatives (Figure 10), show similar activity and are employed in medical 
application.19 
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Figure 10: Colchicine derivatives 
The development of new drugs that act in the same manner as colchicine is additionally 
complicated because the binding site and the mechanism which leads to the disruption 
of the microtubule polymerization dynamics is not completely elucidated.22 It is known 
that colchicine binds irreversible at a binding site at the β-tubulin subunit which leads to 
a partial unfold of the carboxy-terminus. This change in the secondary structure 
prohibits microtubule formation.23 Also, the helical twist within the colchicine core 
structure is necessary for tubulin-binding. Berg et al. isolated the atropisomers of 
desacetamidocolchicine (aR-36, aS-37, Figure 11) and this research group was able to 
show that only the aR enantiomer is active and interacts with tubulin at the 
characteristic binding site.24 
 
Figure 11: Atropisomers of colchicine 
1.5. Biological background 
1.5.1. Tumorigenesis 
Tumorigenesis is a complex multistep process and starts with a single mutation in a 
single cell. The development of cancer can be considered as a microevolutionary 
process. The whole process is based on the Darwinian principles of evolution; 
mutations and natural selection have advanced the evolution of living organisms for 
billions of years.25  
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Cancer cells show two heritable characteristics: (1) reproduction is not stopped by the 
confinements of cell growth, which are common in a healthy cell. Tumor cells evolve 
mechanisms for uncontrolled cell division and (2) they invade and occupy areas 
normally arranged for other cells. Such aberrant cells that proliferate without 
consideration of cell growth signals give rise to a tumor or neoplasm. Cells at that 
cellular state are called neoplastic cells.26 As long as these cells stay in their area or 
tissue the neoplasm is called benign tumor. A tumor is classified as cancer from the 
time when cells have achieved the ability to migrate into surrounding tissue; the tumor is 
called malignant. The competence to invade into other tissues is a crucial characteristic 
of cancer cells. They aim at the possibility to enter blood or lymphatic vessels and form 
secondary tumors at another area in the body, so called metastases. At that state of 
tumorigenesis, cancer is hard to be kept under control and metastases often kill the 
cancer patient.27,28  
Cancer always starts with a primary tumor but a single mutation is not enough to cause 
cancer. There must be an appreciable number of independent genetic incidents during 
the lifetime of a single cell. Living organisms could not survive if just one mutation would 
transform a healthy cell into a rapidly proliferating tumor cell. Tumor progression is a 
multistep process, at each stage a cell gains a further mutation which affords a benefit 
over its neighbouring cells and an advance to invade in its environment. Repeated 
rounds of mutation and cell division follow, finally presenting a clone of malignant 
cancer cells. Each of these steps either enhances cell proliferation or decreases cell 
death in a single cell, so its progeny become the dominant clone in the tumor.29 
When a tumor has reached a certain size it must create possibilities for an adequate 
blood supply to get the required oxygen and nutrients for its survival. This process is 
called angiogenesis. It is necessary to transmit angiogenetic signals. Within the cell pro-
angiogenetic factors such as the vascular endothelial growth factor (VEGF) are 
activated and transcribed. The transcribed proteins are secreted out of the tumor cell, 
attract endothelial cells and start stimulation for the growth of new blood vessels. These 
newly formed blood vessels accommodate the tumor with nutrients and oxygen but they 
are also a possibility for the cancer cells to migrate from the original tissue to other 
regions of the organism. This is one way for tumor metastasizing.27,30 
The human genome comprehends cancer-critical genes, which prevalently contribute to 
the development of cancer. These cancer-critical genes can be divided into two groups. 
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Genetic instability of proto-oncogenes leads to a gain-of-function mutation; too much 
activity of the gene product drives a cell toward cancer. The mutated and 
overexpressed forms of these genes are called oncogenes. The second class are tumor 
suppressor genes. A loss-of-function mutation can indicate the evolution of cancer. 
One of the most important tumor-supressor genes, which is mutated in nearly all human 
cancers, is the gene p53. This gene was named after the molecular mass of its protein 
product. The protein p53 is a cell cycle control protein and the loss of its activity is 
usually dangerous because it permits a cell with DNA-damage to pass through cell 
cycle and undergo mitosis. The second crucial point is that p53 mutated cells gain the 
ability to escape apoptosis. As a result of these two points cell division affords two 
genetically instable daughter cells, where further cancer-promoting mutations can occur. 
These cells, because of an accumulation of mutation, often develop a resistance 
against anticancer drugs.31,32 
The first known human oncogene was the mutated form of the proto-oncognene Ras. 
This gene is mutated in about one of five human cancers. Ras-proteins are monomeric 
GTPases, which are a part of the cell-signaling system and transmit signals from the 
cell surface to the cell interior. GTP-binding proteins are switched “on” when GTP is 
bound (actively signalling) and remain in “off” state when GDP is bound. Ras, and 
therefore all GTP-binding proteins, with bound GTP has an intrinsic GTPase activity and 
shuts itself off by hydrolyzing the bound GTP to GDP. The Ras oncogenes which were 
isolated from human tumors mostly possess point mutations. These mutations cause 
the overactive Ras protein, which is not able to hydrolyse the bound GTP to GDP, to 
inactivate itself. 
Mutations in oncogenes are dominant, because they make the protein hyperactive and 
the change of only one of the two gene copies leads to the described effect. On the 
other hand mutations in tumor-suppressor genes are usually recessive. Both gene 
copies must be deleted, inactivated or silenced epigenetically to achieve the effects 
which are common in cancer cells. 32,33 
1.5.2. The Cytoskeleton – Microtubules 
In a living eukaryotic cell some crucial processes such as cell division, maintenance of 
cell shape, motility, physical robustness, interaction with the environment and correct 
internal structure must be organized. All these abilities necessary for optimal function of 
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a cell are arranged by diverse functions of the cytoskeleton which comprehends three 
types of protein filaments: (1) intermediate filaments, which are responsible for the 
mechanical strength of a cell, (2) microtubules determine the optimal position of 
membrane-enclosed organelles. These protein filaments also arrange the transport of 
vesicles, organelles and proteins within the cell and they play a crucial role at the 
transition from meta- to anaphase during the cell cycle, when the sister chromatids are 
pulled towards the spindle poles. And (3), the last class of protein filaments of the 
cytoskeleton are the actin filaments, also known as microfilaments. They are 
responsible for the stability of the cell shape, necessary for the definition of cell polarity 
and cell migration and they also form the contractile ring to form two daughter cells 
during cytokinesis.34 
The whole cytoskeletal system would not work without the hundreds of accessory 
proteins that link the filaments to other cell components, as well as to each other. The 
optimal function of the cytoskeleton is essential during cell cycle. It can be imagined that 
because of the fast reorganization of a cell in all sections of the cell cycle the three 
protein filaments must be dynamic polymers. Each type of cytoskeletal filament is 
assembled from small soluble subunits. These small subunits diffuse rapidly within the 
cytoplasm so structural reorganizations and reassembling can be performed quickly.35 
Microtubules are built of protein subunits called tubulin. The tubulin subunit itself is a 
heterodimer composed of closely related globular proteins known as α- and β-tubulin, 
held together via noncovalent interactions. The polymerization process starts with the 
relatively slow formation of a small microtubule nucleus. Nucleation is followed by rapid 
elongation at both sides of the microtubule nucleus and finally a hollow cylindrical 
structure built from 13 parallel protofilaments is formed (Figure 12).20 
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Figure 12: Microtubule formation36 
Microtubules have two different ends, one is the so called plus-end where β-subunits 
are exposed and the second is the minus-end where α-subunits are facing the solvent. 
Elongation from the plus-end proceeds faster than from the minus-end.36 
This nucleation-elongation process is very complex and requires energy. Both, α- and 
β-monomer have a GTP-binding site. Hydrolysis of bound GTP to GDP at the time of 
polymerization when tubulin with bound GTP adds to the microtubule end makes the 
energy available which is needed for this dynamic process. The free phosphate moiety 
is split off from GTP, but the hydrolyzed nucleoside diphosphate remains at the binding 
site within the filament structure. It can easily be differentiated between two forms of 
subunit structures. The first is the “T-form” with bound GTP and the second is known as 
the “D-form” interacting with GDP after hydrolysis of the triphosphate. In living cells 
most of the free subunits are usually in the T-form, because the free concentration of 
GTP is about tenfold higher than that of GDP. The subunit on the end of a filament can 
exist in T- or D-form. The hydrolysis state is determined by the rate of hydrolysis in 
comparison to the rate of subunit addition. When the filament is growing rapidly, 
hydrolysis can be too slow and a new subunit will be added at the polymer end before 
GTP has been cleaved in the previously added subunit. The tip of the polymer is 
existent in the T-form and forms a so called GTP-cap. However if the addition rate is 
slow, GTP-hydrolysis occurs before the next tubulin-subunit is added to the microtubule 
end and the filament end is available in D-form.34,37 
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The function of microtubules in a living cell is predominantly determined by their 
polymerization dynamics. Two forms of non-equilibrium dynamics can be differentiated. 
The so called “dynamic instability” means that a microtubule end undergoes alternating 
periods of slow growth and rapid shrinkage. Subunits are added and lost at the same 
end of the microtubule. 
The second form of dynamic behaviour is filament treadmilling. At a particular subunit 
concentration in the cytoplasm, the filament growth at the plus-end exactly balances the 
filament shortening at the minus-end. In other words the subunits undergo a net 
assembly or net growth at the plus-end and a net disassembly or shrinkage at the 
minus-end at an identical rate. During the “steady state treadmilling” a constant rate of 
energy in form of GTP-hydrolysis is needed while the total length of the microtubule 
filament remains unchanged.36,38 
Dynamic instability as well as treadmilling depends on the ratio of the free subunit 
concentration and the rate constant. While treadmilling the range of free subunit 
concentration is higher than the critical concentration of the T-form but lower than the 
critical concentration of the D-form. Subunits are added at the plus-end (in T-form) and 
at the same time at the minus-end tubulin-subunits in the D-form are lost. On the other 
hand during the dynamic instability status a constant free subunit concentration can be 
observed. A constant switch between growing, rescue state, and shrinking, also called 
the catastrophe situation, can occur.35,39 
Microtubules have their origin and start nucleation at a specific intracellular location, the 
microtubule-organizing center (MTOC). In eukaryotic cells the MTOC is called the 
centrosome. Nucleation and polymerization, from the minus-end at the centrosome to 
the plus-end toward the cell periphery, occur in a star-like conformation.34 
1.5.3. Microtubules – their important role in mitosis 
The cell cycle can be divided into two general sections, the interphase and the M-phase 
(M for mitosis). The interphase includes the S-phase (S for DNA synthesis), where the 
replication of the chromosomes and the duplication of the centrosomes occur, and the 
two gap phases (G1-and G2-phase). Cells have the possibility to enter a rest-phase, 
known as G0, if extracellular conditions are inappropriate for cell division. Cells can stay 
in this phase for a very long time, even years, before they restate cell proliferation. After 
completion of the interphase the chromosomes must be separated into two equivalent 
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daughter cells during M-phase. The M-phase includes two important processes: (1) 
nuclear division, or mitosis, the distribution of the sister chromatids and cytoplasmatic 
division, and (2) cytokinesis where the two newly formed cells are constricted. 
The M-phase is further divided into six phases: During prophase the replicated 
chromosomes are condensed and the mitotic spindles are formed outside of the 
nucleus. The starting signal for the prometaphase is the rapid breakdown of the nuclear 
envelope. The spindle microtubules start to interact with the kinetochores of the sister 
chromatids. During metaphase the chromosomes are forming the metaphase plate at 
the equatorial plane of the cell. The spindle microtubules are responsible for the 
transport of the chromosomes to their position at the equator of the cell. During 
anaphase the sister chromatids are separated and they are moving towards the spindle 
poles, pulled by microtubules. In telophase the separated chromosomes have reached 
the spindle poles and the division of the cytoplasm begins with the formation of the 
contractile ring. During cytokinesis the two daughter cells are formed by the contractile 
ring of actin and myosin (Figure 13). 
This shows that microtubules are important in each sequence of the M-phase. 
 
 
Figure 13: Cell cycle 
The chromosome segregation depends on the optimal function of the mitotic spindle. 
The core of this mitotic spindle is a bipolar formation of microtubules. The minus-ends 
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are lying at the spindle poles, which are organized by centrosomes, and the plus-ends 
are reaching starlike into the cell periphery. 
There are three different classes of mitotic spindle microtubules in an eukaryotic cell. 
The kinetochore microtubules build the connection between the sister chromatides and 
the spindle poles. The interpolar microtubules arise from both spindle poles and 
interlock at the equatorial plane over their plus-ends. The third group of spindle 
microtubules are the astral microtubules. Those radiate outward from the centrosomes 
and are interacting with the cortex for optimal position of the spindle poles during 
mitosis.34,40 
The mitotic spindles would not be able to carry out their task without the support of two 
protein families called microtubule dependent motor-proteins. One family is called the 
kinesin-related proteins, which are moving from the spindle poles towards the plus-end 
of microtubules and the other family is known as the dyneins, moving in the opposite 
direction to the minus-end.41 
1.5.4. Antimitotic drugs 
A living cell would not be able to survive without an operating network of dynamic 
polymerizing microtubules. Antimitotic drugs are agents that distort the polymerization 
process of spindle microtubules and thereby mitosis is prohibited. The explanation why 
these drugs are effective against cell division is because the polymerization dynamics of 
spindle microtubules are much more active than cytoskeletal microtubules; 50% of the 
tubulin subunits of the filamentous spindle microtubules are exchanged with the soluble 
pool within 15 seconds.1 
A large number of natural products with chemically diverse structures bind to soluble 
tubulin subunits and/or the filament form of the polymer. By binding to either the free 
form or filamentous form the microtubule formation is driven towards the toxin binding 
form. If the drug binds to soluble tubulin it prevents their assembly to filaments and vice 
versa while if the drug binds to tubulin incorporated into the microtubule lattice, 
depolymerization will not occur. Because of the different effectiveness of these agents, 
antimitotic drugs can be divided into two main groups: The first comprises microtubule-
destabilizing agents, among those are the Vinca alkaloids (vinblastine, vincristine, 
vinorelbine, vindesine and vinflunine), colchicine and the combretastatins. The second 
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group is known as microtubule-stabilizing agents. Known representatives are paclitaxel 
(taxol), the epothilones, laulimalide and discodermolide.36 
This classification of microtubule interacting drugs into microtubule-stabilizing and 
destabilizing agents can lead to confusion. It was found that some antimitotic agents 
which increase or decrease microtubule formation at high concentrations, suppress 
microtubule polymerization at 10-100-fold lower concentrations. It is believed, that the 
growth of tumors is inhibited predominately by suppression of spindle microtubule 
dynamics. As a result mitosis is slowed down or blocked at the transition from 
metaphase to anaphase and apoptotic cell death. All compounds named above bind to 
tubulin on specific binding sites. It can be distinguished between three main binding 
sites, which are named according to their best known ligands the Vinca-, colchicines-, 
and taxol-sites.42 
Vinblastine binds to the β-tubulin subunit between amino acids 175 and 213.43 
Paclitaxel (taxol) has two interaction-sites on β-tubulin, an N-terminal unit and between 
amino acids 217-231. Colchicine binds between the taxol- and vinca binding site.44,45 
1.5.5. Microtubule-destabilizing agents 
Vinca alkaloids and their synthetic analogs 
The first natural products which were used in clinical therapy as antimitotic drugs were 
the Vinca alkaloids vinblastine (1) and vincristine (2, Figure 14). These complex 
compounds were isolated from the leaves of the periwinkle plant Catharanthus roseus 
(L.) G. Don, also known as Vinca rosea.46 The leaves of Vinca rosea were used in 
naturopathy since the seventeenth century. The antimitotic effect and possible 
application as chemotherapeutic agent was discovered in the late 1950s by two 
independent research groups, one at Eli Lilly Research Laboratories and the second at 
the University of Western Ontario. These two compounds, vinblastine and vincristine, 
were introduced into clinical oncology in the late 1960s and remained in widespread 
clinical use up to present.1 
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Figure 14: Vinca alkaloids used in clinical therapy 
Vincristine and vinblastine show very similar structures and mechanisms of action in 
cancer cells but despite this fact they show different toxicological properties and 
application in chemotherapy. Vinblastine is used in the treatment of Hodgkin´s disease 
and in combination therapy against metastatic testicular tumors while vincristine is used 
in the treatment of leukaemia and lymphomas.36 
In search of related compounds with high biological activity which are effective in other 
cancer cell lines as well, several derivatives were synthesized and some of those 
semisynthetic analogs are also in clinical use (Figure 15). Vindesine (38) was the first 
derivative introduced in cancer therapy. It is used in combination therapy for treatment 
of leukaemia, lymphoma and non-small-cell lung cancers (NSCLC).47 Vinorelbine (39) is 
used for NSCLC, metastatic breast cancer and ovarian cancer48-50 whereas vinflunine 
(40), the fluorinated derivative, is in clinical development.51 
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Figure 15: Derivatives of the vinca alkaloids in clinical use 
The biological activity of the vinca alkaloids can be elucidated by effective binding to the 
β-subunit of tubulin dimers, in a region called the Vinca domain. They interact rapidly 
and reversibly with soluble tubulin, which induces a conformational change and leads to 
the formation of paracrystalline aggregates. The number of free tubulin dimers available 
for microtubule polymerization declines and the drug increases the affinity of tubulin for 
itself. The equilibrium is shifted toward disassembly and microtubule shrinkage. The 
described phenomena are noticed in cancer cells exposed to high drug concentration 
(for example, 10 - 100 nM in HeLa cells). As a result the dividing cancer cells are 
blocked in mitosis with condensed chromosomes. This mechanism was thought to be 
responsible for effecting apoptotic cell death for many years. However, recent 
investigations have shown that at low but clinically relevant concentrations (for example, 
IC50 0.8 nM in HeLa cells) depolymerization of the spindle microtubules does not 
happen; nevertheless, mitosis is blocked at metaphase and cells die by apoptosis.52 
Several studies were performed to investigate if vinca alkaloids also bind directly to 
microtubules. It was found that vinblastine binds to the microtubule plus-ends with very 
high affinity at low drug concentration. It is very important, that the interaction of only 
one or two molecules of vinblastine per microtubule reduces both treadmilling and 
dynamic instability by about 50%. At those low drug concentrations microtubule 
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depolymerization does not occur. This disruption of spindle microtubule dynamics 
blocks mitosis.53 
Marine natural products binding on the Vinca domain 
Marine organisms are a rich source of antitumor compounds. Many of these compounds 
are in preclinical or clinical stage of development.54,55 They show different points of 
action in a living cell but several compounds were found binding at the Vinca domain, 
including the halichondrins, the dolastatins, the hemiasterlins, the cryptophycins, and 
the spongitastins among others. In this section just a few examples of the variety of 
marine natural products which bind on the Vinca domain will be described. 
The macrolide polyether halichondrin B (41, Figure 16) was isolated from the marine 
sponge Halichondria okadai with remarkable in vivo antitumor activity.56 The natural 
sources of this compound are not very high, so the development of the total synthesis57 
was a great progress and opened the doors for the preparation of structurally simpler 
analogs that show comparable potency as anticancer drugs. The truncated halichondrin 
B derivative eribulin mesylate (42, E7389) was found to act like its parent compound as 
an inhibitor of tubulin polymerization. Eribulin mesylate is in clinical phase III for the 
treatment of prostate, sarcoma, breast, NSCL and ovarian cancers.58  
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Figure 16: Compounds binding on the vinca domain I 
Dolastatin 10 (43, Figure 17) was isolated first by Pettit and co-workers from the sea 
hare Dolabella auricularia.59 This complex compound also inhibits tubulin polymerization 
by binding near the Vinca domain.60 Dolastatin entered clinical phase I in the 1990s but 
the results were not encouraging.55  
Many derivatives of the dolastatins were synthesized, among which TZT-1027 
(auristatin PE, soblidotin, 44) and tasidotin (45), a dolastatin 15 analog, have entered 
clinical trials.61 
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Figure 17: Compounds binding on the vinca domain II 
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Hemiasterlin (46, Figure 18) was isolated first by Kashman from the South African 
sponge Hemiasterella minor.62 This tripeptidic compound interacts with the same tubulin 
binding site as the dolastatins. Many synthetic analogs have been prepared and HTI-
286 (47) is under clinical trials.63 
 
Figure 18: Compounds binding on the vinca domain III 
Cryptophycin-1 (48, Figure 19) was isolated from the cyanobacterium Nostoc sp. and 
was first described as an antifungal drug.64 After further investigations antimitotic and 
cytotoxic activity could be demonstrated. The cryptophycins are very potent antimitotic 
agents which bind very strongly and mainly irreversibly. These compounds also show 
activity against MDR-cancer cell lines.65 
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Figure 19: Compounds binding on the vinca domain IV 
Compounds binding at the colchicine site 
Colchicine (33) has already been described in section 1.4.2. Up to present, the natural 
product is used in the treatment of acute gout. However, because of its high toxicity 
neither the natural product nor compounds that interact with the colchicine domain (for 
example the combretastatins) are used in clinical treatment of cancer. Colchicine acts in 
the same manner as described for the vinca alkaloids. It depolymerizes microtubules at 
high concentrations and stabilizes microtubule dynamics at low concentrations.36  
Colchicine inhibits tubulin polymerization substoichiometrically. It forms a final-state 
tubulin-colchicine complex, which is mainly irreversible. This complex copolymerizes 
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into the microtubule lattice and microtubule dynamics are suppressed because the 
colchicine-tubulin complex binds more tightly to its tubulin neighbors than free tubulin 
subunits.66 
The structural components within the colchicine skeleton required for the formation of 
the complex were analyzed by SAR studies. These studies came to the result, that the 
9-keto functionality and the methoxy groups at C-1, C-2, and C-10 are necessary for 
effective tubulin binding. The acetamido function at position 7 is not required and can be 
substituted by other functional groups. However, the stereochemistry must be 
conserved. This fact is not clearly understood but it is thought, that the overall 
conformation of the molecule must be maintained. Ring B is responsible for irreversible 
tubulin binding and the general toxicity. The tropone ring C can be substituted by a 
similar substituted benzene ring without losing the antimitotic activity (Figure 20).1 
 
Figure 20: Structure of colchicine 
The combretastatins described above bind to the colchicine binding domain. One of the 
shared functionalities is the trimethoxyphenyl ring. The tropone ring of colchicine is 
substituted by an aromatic ring system with different substitution patterns in the 
combretastatins and the most potent compound is CA-4. Structure-activity relationship 
is described in section 1.6. Two further compounds that also bind at the colchicine 
binding site are in clinical test phases. In addition to microtubule destabilizing effects, 2-
methoxyestradiol (49, Figure 21) shows promising antiangiogenic activity and is in 
clinical phase I.67 The second potent compound is methoxybenzene sulfonamide 
derivative ABT-751 (50). It is an orally active sulfonamide antitumor agent that is 
currently in a phase I clinical trial.68 
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Figure 21: Compounds binding at the colchicine binding site 
1.5.6. Microtuble-stabilizing agents 
Compounds binding at the taxane site 
Taxanes 
Paclitaxel (Taxol, 3) and its semisynthetic analog docetaxel (51) were the most 
important natural products introduced in cancer chemotherapy in the late twentieth 
century. Taxol was isolated first in 1967 by Monroe Wall and Mansukh Wani from the 
bark of the pacific yew tree Taxus brevifolia.69 In 1979, Schiff et al. found that paclitaxel 
acts as an antimitotic agent and disturbs the microtubule polymerization process.70 
Enormous supply problems complicated the entering of the potent natural compound 
into clinical use. The concentration of taxol in the bark of Taxus brevifolia is very low 
and the extraction process is complex and expensive. The tree must be cut for isolation 
and it is a slow growing plant. It was found that a very similar natural product, 10-
deacetylbaccatin III (52), could be isolated from the twigs and needles of the European 
yew, Taxus baccata. Through a semisynthetic route 52 can be transformed to taxol as 
well as to docetaxel (Scheme 1).71,72 
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Scheme 1: Semisynthetic route of taxol and docetaxel 
The taxanes do not show strong interaction with soluble tubulin subunits, but they bind 
with high affinity to the β-subunit of tubulin, incorporated into the microtubule filament. 
More precisely, these important compounds bind to the interior face of the microtubule 
cylinder, stabilizing the microtubule and increasing microtubule polymerization. By 
binding to tubulin, taxol induces a conformational change in the subunit which leads to 
an increase in affinity for neighboring tubulin molecules.73 The exact binding site is 
known because Nogales et al. were able to determine the crystal structure of tubulin 
complexed with paxlitaxel.74 
The increase of microtubule polymerization induced by taxol binding on the interior 
surface of microtubules is associated with nearly stoichiometric binding of the natural 
product. This indicates a very high taxol concentration. In contrast to that phenomenon 
it was found that the binding of a substoichiometric number of taxol molecules stabilizes 
the polymerization dynamics without increasing microtubule polymerization.75 The 
suppression of microtubule polymerization dynamics, or hyperstabilization of 
microtubules, leads to mitotic arrest and cytotoxicity in proliferating cells which die by 
apoptotic cell death. 
In the last years several taxol derivatives were synthesized and some of them entered 
clinical trial. 
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Epothilones 
The epothilones A (53, Figure 22) and B (54) are 16-membered macrolides isolated first 
in 1993 from the myxobacterium Sorangium cellulosum. They show the same 
mechanism of action as taxol in vitro and also in cultured cells.76 The epothilones show 
several advantages over the taxanes such as activity against taxol resistant cell lines, 
higher water solubility and simpler structures, so the synthesis of derivatives is much 
easier.77 
On the other hand the natural epothilones show some limitations in clinical use. The 
most important confinement is their metabolic lability, because of the hydrolysis of their 
lactone ring by esterases in living cells. So the tendency goes towards the synthesis of 
metabolically more stable lactam analogs. Ixabepilone (BMS-247550, 55) was already 
used in clinical trials in paclitaxel-resistant colorectal, metastatic breast, and non-small-
cell lung cancer.1,78 The second limitation is the poor water solubility, as an example the 
more water-soluble amino derivative of epothilone B, BMS-310705 (56) has entered 
clinical test phases.79 
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Figure 22: The epothilones and derivatives in clinical use 
This was a short overview of the most important antimitotic agents in clinical use or trial 
but it has to be pointed out that the list is far from being complete. The discussion of all 
these chemically diverse natural products should demonstrate that tubulin binding drugs 
are crucial in cancer therapy today. 
1.5.7. Antivascular effects  
For more than 50 years researchers are in search of chemotherapeutic agents that 
affect rapidly proliferating cancer cells with low levels of toxicity to healthy cells. Drugs 
with antivascular effects, also known as antiangiogenic drugs that cause the rapid and 
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selective shut down of tumor blood flow, could be the desired breakthrough in cancer 
chemotherapy.80 
The tumor vasculature is an important target in cancer therapy, because many tumor 
cells are provided with oxygen and nutrients through that system, which is essential for 
cell survival. New blood vessels, built via angiogenesis, are also a possibility for tumor 
metastasis.81 
Two different approaches exist to inhibit vascular function. One is the development of 
new agents that inhibit the accumulation of new blood vessels, disrupting angiogenesis. 
The second possibility is an antivascular approach using vascular-disrupting agents 
(VDA). The aim of both approaches is the rapid shut down of existing tumor 
vasculature. Especially tubulin-targeted compounds show antivascular activity. Several 
low-molecular-weight VDAs are in clinical trial or entered preclinical test phases, among 
those combretastatin A-4 phosphate (CA-4-P, 6), combreatstatin A-1-phosphate (CA-1-
P, Oxi4503, 5), ZD6126 (8), AVE8062 (7), flavone acetic acid (FAA, 57), DMXAA 
(58).11,82 
The antivascular effects of CA-4-P, AVE8062 and CA-1-P in ectopically (in an abnormal 
place, outside the tissue of origin) and orthotopically (within the tissue of origin) 
transplanted tumors, spontaneous tumors and vascularized metastases were proved 
partially at doses less than one-tenth of the maximum tolerated dose.81,83 The primary 
effect of VDAs is a very fast reduction of tumor blood flow and extensive tumor cell 
necrosis (unnatural cell death). For example CA-4-P (6) can decrease the blood flow 
significantly within 5 minutes of drug exposure in animal systems. The complete 
vascular shut down is noticed within 20 minutes.84 
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Figure 23: Vascular disrupting agents (VDAs) 
All of the described compounds seem to damage the tumor vasculating system instead 
of normal, healthy blood vessels. It is most likely that morphological and functional 
changes in the endothelial cytoskeleton of cancer cells in vivo are responsible for the 
fast breakdown of tumor blood flow.85 
1.6. Combretastatins – Structure-Activity Relationship 
CA-4 (4) was found to be the biologically most potent compound within the 
combretastatin family. 
CA-4 is capable of inhibiting microtubule assembly at nanomolar concentrations. Table 
1 shows the mean value of 60 human tumor cell lines evaluated in the National Cancer 
Institute (NCI).86 The GI50-value represents the 50% growth inhibitory concentration. 
Combretastatins Mean value GI50 (x10-8M) 
A-1 (12) 1.62 
A-2 (13) 3.16 
A-4 (14) 0.32 
A-5 (15) 165.00 
A-6 (16) >10000 
Table 1: GI50-values of combretastatins86 
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Hundreds of CA-4 derivatives have been synthesized up to present. Their screening 
has allowed to establish a detailed SAR profile,7,87-89 which can be summarized as 
followed: 
 
Figure 24: CA-4 analogs for SAR-studies 
• CA-4 is only active in cis-form. 
• The 3,4,5-trimethoxy substitution pattern on ring A is essential for antimitotic 
activity. 
• The 4-methoxy-3-X-substituted phenyl ring B is indispensable for potent 
cytotoxicity. (X=H, OH, NH2, amino acid, phosphate or other moieties for better 
water solubility) 
• The two aromatic ring systems must be separated by a two-carbon-bridge. 
CA-4 shows potent cytotoxicity against a wide range of human cancer cell lines 
including multi-drug-resistant (MDR) cancer cell lines. MDR cancer cell lines show a 
resistance of antineoplastic agents, drugs that combat the growth of tumors. So-called 
ATP-binding cassette proteins (ABC-proteins) discharge cytotoxic molecules from the 
cancer cell. The intracellular drug concentration is always held below a cell-killing 
threshold. 
1.7. Combretastatin analogs 
CA-4 does not show very strong in vivo efficacy. This is a consequence from, first, its 
high lipophilicity and poor water solubility and second, from the isomerization of the cis-
double bond to the thermodynamically more stable trans-isomer.7,90 Researchers in this 
field were challenged to synthesize better alternatives to the natural compound with the 
goal of disposing these negative properties. As a result innumerable CA-4 analogs have 
been synthesized in the past years, and some of them, for example Oxi-4503 (5), CA-4-
P (6) and AVE8062 (7), as described earlier, have already entered clinical trials or 
preclinical test phases.  
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The following two figures (Figure 25, Figure 26) only show a small cutout of the variety 
of CA-4 analogs.  
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Figure 25: CA-4 analogs I 
Figure 25 shows the incorporation of different moieties on the two aromatic ring 
systems, most of them for better water solubility (60-90). The connecting two-carbon 
bridge was substituted by a carbon-oxygen (78-82) respectively by an oxygen-
connectivity (83), or one of the hydrogen atoms of the sp2-hybridized carbon atoms of 
the original connection were substituted by different functionalities (84-90).91-94 
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Figure 26: CA-4 analogs II 
The incorporation of heterocycles (Figure 26, 91-96) on the connecting carbon bridge 
prevents the system from cis-trans-isomerization, but the disadvantage of that approach 
is that the polarity of the whole molecule is changed compared to the natural product.95-
100 
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1.8. Cyclopropane and cyclobutane synthesis 
Small rings are common structural motifs of natural products and the synthesis of 
cyclopropanes or cyclobutanes is often an important task in total synthesis. 
In the following section different cyclopropanation reactions will be discussed and the 
[2+2]-cycloaddition as one possibility for a cyclobutane synthesis will be described.  
1.9. Cyclopropanes – a theoretical consideration 
Cyclopropanes are highly strained molecules. Most of this strain is a consequence of 
the deviation of the bond angles from the ideal tetrahedral angle of 109.5°. The internal 
angle in the planar cyclopropane is 60°, so the C-C bond energy is reduced and as a 
consequence the compound is more reactive than other cycloalkanes such as 
cyclohexane or cyclopentane. All C-H bonds are eclipsed which adds to the ring strain 
already present. Rotation around the C-C bonds is not possible and so all C-H bonds 
are forced in the eclipsed conformation. 
The first detailed studies about the nature of cyclopropanes were published by Coulson 
and Moffit.101 They came to the result that the C-C bonds of the cyclopropane ring are 
formed by the interaction of bond orbitals which are relatively rich in p-character leading 
to the minimization of the interorbital angle as well as the conventional bond angle. The 
reduction of the bond angles to 60° is possible because of the increase of p-character, 
but as a result the C-H bonds gain more s-character and are shortened. In 
cyclopropane the maximum electron density between two adjacent carbon atoms does 
not lie on the internuclear axis (Figure 27, shown in red) and such bonds are known as 
bent bonds. The interorbital angle in cyclopropane is 104°. The bending can be 
confirmed by X-ray crystallographic studies of cyclopropane derivatives. It could be 
demonstarted that the deformation density of the C-C bonds lies outside the 
cyclopropane triangle. Cyclopropane rings always have C-C bonds that are shorter than 
C-C single bonds in larger rings or in alkyl chains, which can be explained in terms of 
bent bonds.102 
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Figure 27: Coulson-Moffitt model of cyclopropane 
A second model for cyclopropane was presented by Walsh.103,104 He constructed a 
model of cyclopropane where sp2-orbitals are directed toward the hydrogens and also 
toward the center of the three-membered ring. The remaining p-orbital lies in plane with 
the three-membered ring as shown in Figure 28. The C-C bonds result from the overlap 
of the sp2 orbitals showing towards the center of the cyclopropane ring and from the 
remaining p-orbitals outside the three-membered ring. It must be noted that this model 
also includes an antibonding overlap (Figure 28). 
 
Figure 28: Walsh model of cyclopropane 
1.9.1. Synthesis of cyclopropane 
Although the cyclopropane ring is a highly strained structure it is found in a wide range 
of natural products including terpenes, pheromones and fatty acid metabolites. The 
cyclopropanation reaction, especially the enantioselective synthesis of cyclopropane 
containing compounds is an interesting and important method in natural product 
synthesis. In the following section different cyclopropanation reactions are described. 
1,3-Elimination of two heteroatoms 
Reductive elimination of 1,3-dihalides with metallic or organometallic reagents as 
reducing agents is a powerful method for the cyclopropane synthesis. The first 
intramolecular Wurtz-reaction was published in 1882. This was the reduction of 1,3-
dibromopropane with sodium in an alcoholic solvent to afford cyclopropane. Varied 
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reaction conditions using zinc dust in methanol, ethanol or higher alcohols give 
substituted cyclopropanes (Scheme 2). 
 
Scheme 2: 1,3-Elimination of two heteroatoms I 
The reaction is a nonstereospecific process and not concerted. The formation of a 
carbanionic organometal compound via metal-halogen exchange is followed by the 
displacement of the halide ion by the organometal species in an SN2 reaction.105  
Various other reagents can be used for reductive debromination, cyclization reactions 
with chrome (II) perchlorate in dimethylformamide / water, lithium amalgam in THF, 
potassium-sodium alloy in THF, alkyllitihium in THF are found in the literature among 
many others. 
The following examples react all in the same manner:  
 
Scheme 3: 1,3-Elimination of two heteroatoms II 
Scheme 3 demonstrates an example for a 1,3-elimination, the reaction of a chloroketal 
with magnesium to form the cyclopropyl derivative 103.106 
 
Scheme 4: 1,3-Elimination of two heteroatoms III 
Scheme 4 shows a cyclopropanation by elimination of a sulfur and an oxygen atom. 
First the carbanion is formed by displacement of the phenylthio group.107 
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Scheme 5: 1,3-Elimination of two heteroatoms IV 
1,3-Deoxystannylation is a stereospecific reaction (Scheme 5) giving 1-methyl-1,2-
diphenylcyclopropane (108).108 
Scheme 6 shows a modification of this destannylation protocol, affording cyclopropane 
111.109 
 
Scheme 6: 1,3-Elimination of two heteroatoms V 
In a similar way (but-3-en-1-yl)trimethylsilan reacts with an acyl halide to cyclopropyl 
ketone 114 (Scheme 7).110 
 
Scheme 7: 1,3-Elimination of two heteroatoms VI 
Hydroboration of an allylic chloride and subsequent treatment of the intermediately 
formed organoborane with aqueous sodium hydroxide gives cyclopropane 117. The 
geometry in the alkene is retained in the resulting product (Scheme 8).105,111 
 
Scheme 8: 1,3-Elimination of two heteroatoms VII 
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A possibility for a cyclopropyl ketone synthesis is the reaction of prop-2-ynyl 4-
methylbenzenesulfonates (118) with trialkylborane and subsequent oxidative cleavage 
of the boron species with hydrogen peroxide and sodium acetate (Scheme 9).112 
 
Scheme 9: 1,3-Elimination of two heteroatoms VIII 
Intramolecular SN2 displacement 
Another possibility to synthesize a cyclopropane ring is via an intramolecular SN2 
displacement (Scheme 10). 
 
Scheme 10: Cyclopropane synthesis via SN2 displacement I 
The anion can be generated next to different anion-stabilizing groups (ASGs) actually 
adjacent to an alkene or an arylthio group, which show only a reasonable stabilizing 
effect. The leaving group can be attached to a primary, secondary or tertiary carbon 
atom (Scheme 11, a-d).113-116 
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Scheme 11: Cyclopropane synthesis via SN2 displacement II 
Cyclopropane synthesis is also possible by an intramolecular epoxide ring opening 
reaction. Scheme 12 demonstrates a double use of the 1,3-elimination reaction, 
affording bicyclo[1.1.0]butanes 136.  
 
Scheme 12: Cyclopropane synthesis by intramolecular epoxide opening 
The geometry of the OMs- and arylsulfonyl groups in 135 is exclusively trans.117 
Another possibility for a cyclopropanation is the intramolecular SN2-reaction from a γ,δ-
unsaturated carbonyl or nitrile compound with a leaving group at the ε-carbon atom. 
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Scheme 13: Synthesis if chrysanthemic acid derivative 
Reaction conditions 140/139 ratio Yield % 
2.5 h, 65 °C 1:1 75% 
1.5 h, 65 °C 
5-10% Pd(PPh3)4 
19:1 70% 
Table 2: Synthesis if chrysanthemic acid derivative – cis/trans ratio 
Scheme 13 shows a synthesis of a chrysanthemic acid derivative. In the presence of a 
catalytic amount of tetrakis(triphenylphosphine)palladium(0), the cis-trans-ratio could be 
shifted toward the cis-chrysanthemonitrile derivative (Table 2).118 
Another procedure for cyclopropane synthesis is a substitution initiated ring-closure 
reaction (SIRC). This is an alkylation followed by a cyclization of an activated methylene 
compound with 1,2-dihaloalkanes. One example is shown in the following Scheme 
14.119 
 
Scheme 14: Substitution initiated ring-closure reaction (SIRC) 
The Michael initiated ring-closure (MIRC) describes a ring closure reaction starting with 
a conjugate addition onto an electron-deficient alkene followed by the elimination of a 
leaving group (LG). The leaving group can be part of the nucleophile or can be 
incorporated into the Michael acceptor (Scheme 15).120 
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Scheme 15: Michael initiated ring closure reaction (MIRC) 
Usually, MIRC reactions give racemic mixtures of cyclopropanes. The cis-trans-ratio 
and the stereoselectivity on the newly formed bond depends on different factors, the 
solvent polarity, the degree of anion-cation association and steric interactions.121 
Due to hyperconjugation the carbanion intermediate has a relatively long lifetime; as a 
result rotation around the C-C bond is possible and inversion can be observed (Scheme 
16). 
 
Scheme 16: Hyperconjugation in MIRC reactions 
Stereospecifity can be observed when kcycl is very high, which occurs with good leaving 
groups. 
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Formation of cyclopropanes by the addition of carbenes to alkenes 
Carbenes can be divided into two groups: so called triplet and singlet carbenes. Many 
carbenes exist in either state, but one may be more common. A sp2-hybridized carbene 
has three sp2-orbitals, which are low in energy, and one high-energy p-orbital, in which 
six electrons must be divided. There are two possibilities, all electrons can be paired in 
the sp2-orbitals or two electrons can remain unpaired with one electron occupying the 
hybridized sp2-orbital and the other the empty p-orbital. These two states describe the 
two classes of carbenes. The orbitals are the same in both cases. Triplet carbenes have 
two unpaired electrons and singlet carbenes have exclusively paired electrons in 
nonbonding sp2-orbitals and an empty p-orbital. 
It depends on the substituents on the carbene in which of the two classes the reactive 
compound falls. For example the methyl carbene (:CH2) is a triplet carbene, which 
means that the triplet state is lower in energy than the singlet state and energy is 
necessary to pair the two electrons. When carbenes are formed during a chemical 
reaction it does not have to be formed in its most stable state, the ground state. 
Otherwise, dichlorocarbene (:CCl2) is a singlet carbene with the singlet state as most 
stable state, the ground state. Singlet carbenes all have electron-rich substituents 
carrying lone pairs which can interact with the free p-orbital of the carbene, forming a 
new lower-energy orbital.  
The electronic structure of carbenes depends on how they are generated. 
Dichlorocarbene (164) is formed via an α-elimination mechanism. Chloroform has 
exclusively paired electrons, in the first step of this elimination mechanism the C-H-σ-
bond breaks, both electrons move to the carbon atom to form the lone pair. The 
carbanion has also all paired electrons. In the following step two paired electrons from 
the C-Cl bond leave and the carbene is formed in the singlet state (Scheme 17).  
 
Scheme 17: Dichlorocarbene formation 
Carbenes react with alkenes affording cyclopropanes. The mechanism of this reaction is 
different depending on whether the carbene is a singlet or a triplet. Singlet carbenes 
react in a concerted manner (Scheme 18). 
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Scheme 18: Reaction of dichlorocarbene  
The reaction is stereospecific, the geometry of the alkene is retained in the product 
(Scheme 19). The Z-alkene gives cis-cyclopropane, which is less stable than the trans-
isomer. 
 
Scheme 19: Reaction of dibromocarbene 
For triplet carbenes the alkene insertion reaction is nonsterospecific and the reaction 
mechanism is not concerted. The carbene adds to the alkene in a radical reaction and a 
diradical (triplet) intermediate is formed. One of the spins must be inverted to form the 
second C-C bond. The intermediate is long living, C-C bond rotation can happen and 
the stereochemistry is lost (Scheme 20). 
Me Me
CX2
Me Me
CHX2
Me Me
CHX2
Me Me
X X
Me Me
X X
triplet carbene triplet intermediate singlet intermediate
slow spin
inversion
fast C-C bond
formation
169 170 171
172 173  
Scheme 20: Reaction of triplet carbenes 
When a carbene is formed by α-elimination it must be in singlet state, but nevertheless 
the triplet state is lower in energy. Most carbene reactions are very fast, carbenes with 
triplet ground states do not have the time for spin-flipping and react in the state they are 
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formed (singlet state). This fact can be observed for :CH2 produced from diazomethane. 
The addition of CH2N2 to a double bond is stereospecific.  
The reaction of a triplet carbene with an alkene can be classified as a radical reaction; 
otherwise, the concerted addition of a singlet carbene can be considered as a [1+2]-
cycloaddition.  
Photolysis of diazomethane generates the reactive carbene species. The photolytic 
decomposition can be catalyzed by metal salts. Palladium(II) acetate is a very effective 
catalyst for the cyclopropanation reaction.122 
 
Scheme 21: Cyclopropanation with diazomethane 
Scheme 21 shows the cyclopropanation on a cyclic olefin, the carbene species attacks 
the less hindered double bond.123 The cyclopropanation with this method proceeds with 
low diastereoselectivity for acyclic olefins. Pietruszka et al. developed a method for 
diastereoselective cyclopropanation of alkenylboronic esters (Scheme 22). 
 
Scheme 22: Diastereoselective cyclopropanation with diazomethane I 
The carbene attacks the double bond from the less hindered side without complexation 
to the bulky boronic ester group (Scheme 23).124 
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Scheme 23: Diastereoselective cyclopropanation with diazomethane II 
Asymmetric cyclopropanation under the same reaction conditions could be arranged 
under the application of the chiral auxiliary (-)- or (+)- ephedrine and α,β-unsaturated 
aldehydes (Scheme 24).125 
 
Scheme 24: Asymetric cyclopropanation of α,β-unsaturated aldehydes 
Simmons-Smith cyclopropanation 
In 1958 Simmons and Smith published the sterospecific cyclopropanation of alkenes 
with diiodomethane and zinc-copper couple in high yield. The reactive intermediate is 
(iodomethyl)zinc iodide (ICH2ZnI) the product of the initial reaction of diiodomethane 
and zinc metal.126 The Simmons-Smith reaction is a very powerful method for 
cyclopropane synthesis. The reaction is stereospecific, so the stereochemical 
information of the alkene is retained in the product. For chiral substrates the reaction is 
highly diastereoselective and the attack occurs from the less hindered side of the 
double bond. In the Furukawa modification diethylzinc and diiodomethane are used as 
reagents with high reproducible results.127 The mechanism of this reaction is shown in 
Scheme 25. The so called Molander modification with iodo- or chloromethylsamarium 
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iodide is the method of choice for chemoselective cyclopropanation of allylic alcohols in 
the presences of other olefins.128 
 
Scheme 25: Furukawa modification of the Simmons-Smith reaction 
The diastereomeric selectivity of the Simmons-Smith reaction in cyclic and acyclic 
systems is strongly affected by allylic alcohol functionalities. The cyclopropanation 
reaction of (Z)-allylic secondary alcohols with zinc or samarium occurs with high 
diastereoselectivity (Scheme 26).123 
 
Scheme 26: Cyclopropanation reaction of (Z)-allylic secondary alcohols  
The diastereomeric ratio (dr) can be explained by the directing influence of the allylic 
hydroxyl group which prevents allylic-1,3-strain. Cyclopropanation of the trans-isomer 
with CH2I2/Et2Zn shows good syn selectivity. The diastereoselectivity depends on the 
steric bulk on the secondary alcohol (194, 196, Scheme 27).129 
 
Scheme 27: Cyclopropanation reaction of (E)-allylic secondary alcohols  
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The cyclopropanation of α,β-unsaturated acetals from tartrate esters was reported by 
Yamamoto (Scheme 28). The diastereoseletivity can be explained by the coordination 
of the Zn-species to the acetal as well as to the adjacent ester carbonyl.130 
 
Scheme 28: Cyclopropanation of α,β-unsaturated acetals 
The asymmetric cyclopropanation of 1-alkenylboronic esters is also reported in 
literature. Subsequent oxidation affords cyclopropanols with high optical purity.131 
 
Scheme 29: Asymmetric cyclopropanation of 1-alkenylboromic esters 
The enantioselectivity for the Simmons-Smith cyclopropanation of 200 is opposite to 
that for the cyclopropanation with diazomethane (Scheme 29) 
Cyclopropanation of allylic alcohols in presence of the chiral ligands S,S-205, R,R-206 
gives cyclopropylcarbinols in excellent yield and high ee (Scheme 30).132 
 
Scheme 30: Cyclopropanation of allylic alcohols in presence of chiral ligands 
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A large number of chiral ligands were used for asymmetric Simmons-Smith 
cyclopropanation and were applied in the synthesis of cyclopropane containing natural 
products. Three examples of these chiral ligands are shown in Figure 29.133-135 
 
Figure 29: Chiral ligands for asymmteric Simmons-Smith reaction 
Cyclopropane synthesis via ring contraction 
1) From four–membered rings  
One possibility for cyclopropane synthesis from four-membered rings is the elimination 
of a one-atom fragment. The reactive intermediate of this reaction is a biradical. The 
cycloalkanone is irradiated with light of a certain wavelength which leads to α-bond 
cleavage and an acyl-alkyl diradical which subsequently decarbonylates and forms the 
ring-contracted cycloalkane. 
 
Scheme 31: Cyclopropane synthesis via elimination of a one-atom fragment 
Acyloin-type cyclization and oxidation with activated DMSO (Albright-Goldman 
oxidation) is followed by irradiation of the resulting α,β-diketone affording the desired 
cyclopropanone (Scheme 31).136 
Another way of cyclobutane ring contraction is by rearrangement of cyclobutyl cations. 
Solvolysis of a tosylcyclobutane (214) occurs via a disrotatory ring opening which gives 
a cyclopropylmethyl cation as an intermediate and finally the cyclopropyl derivative is 
formed (Scheme 32).137 
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Scheme 32: Cyclopropane synthesis by rearrangement of cyclobutyl cations I 
Under acidic conditions endo-216 gives mainly 2-acetoxynorcaranes 217 and 218 
(Scheme 33) .137 
 
Scheme 33: Cyclopropane synthesis by rearrangement of cyclobutyl cations II 
This reaction type often gives a mixture of a varity of products depending on the 
stabilized cation. 
A very interesting class of ring contractions is the reaction of a substrate with an 
electron-donating group connected to one ring carbon atom and a leaving group, an 
electron-withdrawing group, on a neighboring carbon in the ring (Scheme 34). Known 
reactions that fall into this category are the acyloin and pinacol rearrangements, the 
benzilic acid and the quasi-Favorskii rearrangement. 
 
Scheme 34: Cyclopropane synthesis in presence of an electron-donating and a leaving group 
Different examples are shown in the following schemes. 
 
Scheme 35: Ring contraction of 2,2-dihalocyclobutanols 
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Scheme 35 shows the ring contraction of 2,2-dihalocyclobutanols with aqueous sodium 
hydroxide. The reaction is stereospecific: exo-alcohols give endo-aldehydes and vice 
versa. The chlorine atom trans to the hydroxyl functionality is displaced.138 
 
Scheme 36: Ring contraction in steroid synthesis 
An example of a ring contraction in steroid synthesis is described in Scheme 36.139 
2) From five–membered rings  
The thermal and photochemical deazetization of 4,5-dihydro-3H-pyrazoles is a very 
important method for cyclopropane synthesis. A simplified mechanism is shown in 
Scheme 37. 
N N N N -N2
diazenyl
diradical
trimethylene
diradical
226 227 228 229
 
Scheme 37: Deazetization of 4,5-dihydro-3H-pyrazoles 
The addition of diazoalkanes to alkenes to form 4,5-dihydro-3H-pyrazoles needs 
activating substituents, electron withdrawing groups such as trifluoromethyl, ester, 
nitrile, nitro substituents. 
This method can be used for the synthesis of optically active cyclopropanes. One 
example, the reaction of diphenyldiazomethane with the corresponding (-)-menthyl 
ester, is demonstrated in Scheme 38.140 
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Scheme 38: Synthesis of optically active cyclopropanes 
Diphenyldiazomethane reacts with (-)-menthyl ester to the diasteromer 231 (94% de). 
Pyrolysis or photolysis of the product and subsequent cleavage of the menthyl moiety 
with lithium aluminium hydride gave the desired product 232 with R configuration. 
This route can be modified to give access to optically active amino acid derivatives 
(Scheme 39).141 
 
Scheme 39: Synthesis of optically active amino acid derivatives 
The addition of diazomethane to 233 gave the spiro-pyrazoline 234 (diastereomeric 
ratio 95:5), after photolysis and subsequent hydrolysis (+)-236 could be isolated. 
3) From six–membered rings  
When a cyclohexyl cation is formed, a three-membered ring can be prepared (Scheme 
40).142 
 
Scheme 40: Cyclopropane synthesis via a cyclohexyl cation 
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Another possibility for cyclopropane synthesis from six-membered rings is the 
photochemical meta-addition of acyclic and cyclic alkenes with benzene.143 
 
Scheme 41: Photochemical meta-addition of anisole with cyclopentene 
Scheme 41 shows the photochemical reaction of anisole (239) with cyclopentene (240) 
to tetracycle 241. Subsequent acidic treatment allows the product to undergo a 
rearrangement affording 242.144 
Cyclobutane 
The C-C-C bond angle in cyclobutane is 90° in contrast to 109.5°, the tetrahedral angle 
in a linear butane molecule. Planar cyclobutane has exclusively eclipsed methylene 
groups, and such a conformation has a maximum torsional strain. The cyclobutane ring 
distorts from that planar conformation to decrease the negative eclipsed interactions, 
but otherwise at the same time the C-C-C dihedral bond angle is reduced resulting in an 
increase of the angle strain. The equilibrium geometry depends on those two competing 
strains. Cyclobutane shows a so called puckered or “wing-shaped” conformation. 
[2+2]-Cycloaddition 
Cycloadditions with 4n π-electrons are allowed if the reaction is carried out 
photochemically. A thermal [2+2]-cycloaddition is symmetrically forbidden. The 
contradicting symmetry of two alkenes can be avoided if one electron is converted 
photochemically into the π*-orbital (Scheme 42). 
 
Scheme 42: Photochemical [2+2]-cycloaddition 
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The symmetry problem is solved by the combination of one excited alkene with another 
in the ground state. The reaction is stereospecific and it proceeds via the least hindered 
transition state. 
Thermal [2+2]-cycloadditions occur in the reaction of a simple alkene with an 
electrophilic alkene. The most important examples are ketenes and isocyanates. These 
compounds possess two perpendicular π-bonds which is the correct angle to allow a 
thermal reaction to occur (Scheme 43). 
 
Scheme 43: Orbitals of ketene and isocyanate for a thermal [2+2]-cycloaddition 
The very acidic proton on dichloroacetyl chloride can be removed with triethylamine. In 
a following E1cB reaction a chloride anion is removed and the desired dichloroketene is 
formed. 
 
Scheme 44: Dichloroketene formation from dichloroacetyl chloride 
The cyclopentene derivative reacts with dichloroketene in a regio- and stereospecific 
manner (Scheme 45). The most nucleophilic atom in the alkene species is connected to 
the most electrophilic atom of the ketene in the resulting product 247.145 
O
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Scheme 45: [2+2]-cycloaddition of a cyclopentene derivative with dichloroketene 
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2. Results and discussion 
2.1. Synthesis of CA-4 
2.1.1. Retrosynthetic analysis 
 
Scheme 46: Retrosynthesis of CA-4 
The synthetic strategy (Scheme 46) is based on the Suzuki-Miyaura palladium 
catalyzed coupling reaction between a alkynylboronic ester, generated in situ from 
acetylenic derivative 249, and arylbromide 250.146 The coupling reaction is followed by 
the second key-step, the hydroboration or catalytic hydrogenation to afford natural 
product CA-4 (4). 
2.1.2. Synthesis of the two aromatic fragments 
 
Scheme 47: Corey-Fuchs reaction 
Initially, the alkyne was introduced via Corey-Fuchs reaction (Scheme 47),147,148 of 
aldehyde 251. However, the reaction afforded the desired alkyne in low yield and the 
method was replaced by a variation of the Bestmann-Ohira-sequence shown in Scheme 
48. The aldehyde reacts in presence of n-BuLi and TMS-diazomethane to afford 
terminal alkyne 249.149 
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Scheme 48: Synthesis of terminal alkyne 249 via a variation of the Bestmann-Ohira-sequence 
We were able to synthesize the aromatic fragment 250 in good yield over four steps as 
shown below (Scheme 49). Protection of guaiacol (252) with Ms-Cl under basic 
conditions gave aromatic derivative 253, deactivated on the ortho-position of the 
methoxy functionality. The following selective bromination in para-position of the 
methoxy-group gave tri-substituted aromatic system 254. In the next two steps 254 was 
deprotected (255) and the Ms-group was substituted by a MOM-group, affording the 
desired product 256.150 
 
Scheme 49: Synthesis of the aromatic fragment 250 
2.1.3. Suzuki-Miyaura coupling reaction 
 
Scheme 50: Suzuki-Miyaura coupling reaction 
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The following step is the coupling reaction of the two before prepared aromatic 
fragments (Scheme 50). Finding reaction conditions which gave acceptable yield was 
tedious. Various conditions tried for that step are listed in Table 3. 
R reagents catalyst solvent T Reaction 
time 
yield 
OH PPh3, n-BuLi151 Pd(OAc)2 pyrollidine 90 °C 150 min 0%, SM 
reisolated 
OH triisopropylborate, 
n-BuLi151 
Pd(PPh3)4 DME 90 °C 14 h 0%, SM 
reisolated 
OMs triisopropylborate, 
n-BuLi146 
Pd(PPh3)4 DME 90 °C 14 h 0%, SM 
reisolated 
OMOM triisopropylborate, 
n-BuLi146 
Pd(PPh3)4 DME 90 °C 2 d 38% 
OMOM triisopropylborate, 
n-BuLi146 
Pd(PPh3)4 DME/THF 
10:1 
90 °C 1 week 0%, 
decomp. 
OMOM triisopropylborate, 
n-BuLi146 
Pd(PPh3)4 DME/THF 
10:1 
90 °C 2 d 56% 
OMOM 9-MeO-9-BBN, 
n-BuLi152 
PdCl2(dpp) THF 75 °C 6 h 33% 
OMOM 9-MeO-9-BBN, 
n-BuLi152 
PdCl2(dppf) THF 75 °C 2 d 20% 
OMOM 9-MeO-9-BBN, 
n-BuLi152 
PdCl2(dppf) DME/THF 
10:1 
90 °C 2 d 26% 
Table 3: Reaction conditions for the coupling reaction of CA-4 
We found that protection of the phenolic hydroxy functionality as MOM-ether is essential 
for a positive result. The free and Ms-protected alcohol did not react under the reaction 
conditions shown in Table 3. For the most potent coupling condition triisopropylborate 
was used as the boron-species, tetrakis(triphenylphosphine)palladium(0) as catalyst 
and a solvent mixture DME/THF, 10:1.146 The reaction mixture was heated to reflux for 
2 days, leading to an acceptable yield (56%) of 248. 
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Scheme 51: Synthesis of CA-4 
As shown in Scheme 51 the palladium catalyzed coupling reaction was followed by 
hydroboration153 or alternatively by catalytic hydrogenation. Both reactions afford the 
desired cis-stilbene derivative 258 in excellent yield. In the final step the MOM-
protection-group was cleaved with a catalytical amount of hydrochloric acid affording the 
natural product CA-4. 
2.2. Synthesis of CA-4-phosphate 
 
Scheme 52: Synthesis of CA-4-P 
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Scheme 52 shows the synthesis of combretastatin analog 6. Derivatization of the 
phenol functionality with dibenzylphosphit and a catalytical amount of DMAP gave the 
dibenzylphosphate of CA-4 (259). Cleavage of the benzyl groups with NaI and TMS-Cl 
and subsequent transformation into the sodium salt for better water solubility, afforded 
CA-4-P (6).154 
2.3. Synthesis of the amino derivative AVE8062 
 
Scheme 53: Coupling reaction to generate the precursor of AVE8062 
Again, key-step is the coupling reaction of the terminal alkyne (249) and aniline 
derivative 260 as shown in Scheme 53. 
Table 4 demonstrates the various conditions tried to find the most efficient coupling 
conditions. 
NHR X reagents catalyst solvent T Reaction time yield 
NHBoc Br 
Triisopropylborat,  
n-BuLi146 
Pd(PPh3)4 
DME:THF 
10:1 90 °C 14 h 
0%, SM 
reisolated
NH2 Br 
PPh3 
n-BuLi151 Pd(OAc)2 pyrollidine 90 °C 5 h 
0%, SM 
reisolated
NH2 Br CuI155 Pd(PPh3)4 piperidine r. t. 1 day 
0%, 
decomp. 
NH2 Br 
9-MeO-9-BBN 
n-BuLi152 PdCl2(dpp) THF 75 °C 12 h 
0%, SM 
reisolated
NHBoc Br 9-MeO-9-BBN152 PdCl2(dpp) THF 75 °C 12 h 3 % 
NH2 I NEt3, CuI156 Pd(PPh3)Cl2 DMF r.t. 20 h 70 % 
Table 4: Reaction conditions for coupling reaction of AVE8062 synthesis 
The Suzuki-Miyaura coupling conditions as described before for the synthesis of CA-4, 
triisopropylborate as the boron species and tetrakis(triphenylphosphine)palladium(0) as 
catalyst, resulted in reisolation of the starting marterials. Also standard Heck reaction 
conditions with triphenylphosphine and palladium diacetate were tried but with not much 
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success.157 We switched from the arylbromide to the more reactive aryliodide and 
changed to Sonogashira coupling conditions with NEt3 as base; CuI and dichloro-
bis(triphenylphosphine)palladium(II) as catalyst.158 Finally, we were able to isolate the 
coupling product 263 in good yield. 
I
OMe
NH2
MeO
MeO
OMe
MeO
MeO
MeO
OMe
NH2
NEt3, CuI,
Pd(PPh3)Cl2
70%
Pd/CaCO3,
H2
60%
MeO
MeO
OMe
OMe
NH2
DIC,
HOBt-H2O,
Fmoc-L-Serin(Ac)
MeO
MeO
OMe
OMe
N
H
MeO
MeO
OMe
OMe
N
H
1.) 2M NaOH, 61%
2.) 4M HCl, 91%
249 262 263
264265
7
O
OH
NH2HCl
O
OAc
NHFmoc
70%
 
Scheme 54: Synthesis of AVE8062 
As described in Scheme 54, coupling of the two aromatic fragments was followed by 
catalytic hydrogenation to afford 264. In the following three steps first the Fmoc- and 
acetate-protected L-serine moiety was incorporated at the amino functionality of the cis-
stilbene giving 265. Furthermore, both protecting groups were cleaved under basic 
conditions with 2M NaOH and finally the hydrochloride was precipitated, affording the 
desired derivative AVE8062 (7).159 
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2.4. Synthesis of cyclopropane derivative (268) 
 
Scheme 55: Cyclopropanation reaction 
Various conditions for the cyclopropanation (Scheme 55) of the double bond on the 
connecting carbon bridge of the MOM-protected CA-4 were investigated (Table 5).  
Reagents Solvent T Reaction time Yield 
CHCl3, 
benzyltriethylammonium 
chloride, NaOH160 
- 50 °C 4 h 0%, decomposition 
ZnEt2, CH2I2161 CH2Cl2 0 °C 12 h 0%, SM reisolated
ZnEt2, CH2I2161 CH2Cl2 r. t. 2 days 0%, SM reisolated
ZnEt2, CH2I2, TFA162 CH2Cl2 r. t. 12 h 0%, SM reisolated
CBrCl3, n-BuLi163 Et2O r. t. 12 h 0%, SM reisolated
Mg, CCl4, TiCl4164 ClCH2CH2Cl 0°C 90 min 0%, SM reisolated
CH2N2, Pd(OAc)2165 Et2O 0 °C 3 h 55% 
Table 5: Reaction conditions for the cyclopropanation reaction 
Standard conditions for carbene formation, (chloroform, a phase-transfer-catalyst and 
NaOH as base160) resulted in decomposition of the starting material. The Simmons-
Smith reaction161 also did not afford the desired cyclopropane derivative and the starting 
material was recovered unchanged even when the Simmons-Smith reagent was 
activated with TFA.162 Also the carbene formation with CBrCl3 and n-BuLi163 as well as 
the TiCl4-Mg-promoted dichlorocarbene transfer of CCl4164 did not show any reaction. 
The cyclopropanation with diazomethane and palladiumdiacetate as a catalyst165 led to 
the desired cyclopropane derivative (266) with 55% yield. 
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MeO
MeO
OMe
OMe
OMOM
MeO
MeO
OMe
OMe
OMOM
HCl
MeO
MeO
OMe
OMe
OH
CH2N2,
Pd(OAc)2
55%
258 266
9
68%
MeO
MeO
OMe
OMe
O
P
O
OBn
OBn
MeO
MeO
OMe
OMe
O
P
O
ONa
ONa
267
268
DIPEA, DMAP,
(BnO)2P(O)H
67%
1.)TMS-Cl, NaI
2.) NaOMe 32%
 
Scheme 56: Synthesis of cyclopropane derivative 268 
The cyclopropanation was followed by the removal of the MOM-protecting-group under 
acidic condition, and the cyclopropyl derivative of CA-4 (9) was isolated. Subsequent 
derivatization of the free phenolic functionality with dibenzyl phosphit and transformation 
of the phosphate into the corresponding sodium salt was done to increase water 
solubility (Scheme 56).154 
The cyclopropane derivative of AVE8062 was prepared as shown in Scheme 57. We 
started with the cyclopropanation, the reaction conditions were described earlier in that 
section, of the Boc-protected cis-stilbene (269). The cyclopropanation was also carried 
out with the unprotected compound. The reaction resulted in decomposition of the 
starting material. The protection group was cleaved, giving 271, and the L-serine moiety 
was introduced following the same procedure as described for the synthesis of 
AVE8062. First the protected serine was incorporated (272) followed by deprotection 
and precipitation of the hydrochloride, affording the desired product 273.159 
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Scheme 57: Synthesis of the cylopropane derivative of AVE8062 (273) 
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2.5. Synthesis of the cyclobutane derivative 
2.5.1. First approach – [2+2]-cycloaddition 
 
Scheme 58: Synthesis of the cyclobutane derivative via [2+2]-cycloaddition 
Key step in this approach (Scheme 58) is the [2+2]-cycloaddition followed by removal of 
the two chlorine atoms by zinc metal and subsequent reduction of the keto-functionality.  
Before reactions were carried out on the actual systems, conditions were optimized on 
model systems. 
Standard dichloroketene-formation conditions on trans-stilbene were tested first 
(Scheme 59, Table 6). 
 
Scheme 59: [2+2]-cycloaddition on trans-stilbene 
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Reagents Solvent T Reaction  time Yield 
dichloroacetylchloride, 
NEt3 
Et2O 0 C° 24 h 0%; SM reisolated 
Zn, 
trichloroacetylchloride166 Et2O 0 C° 5 h 0%; SM reisolated 
Zn, POCl3, 
trichloroacetylchloride167 
Et2O reflux 3 h 0%; SM reisolated 
Zn-Cu, POCl3, 
trichloroacetylchloride167 
Et2O reflux 3 h 0%; SM reisolated 
Table 6: Reaction conditions [2+2]-cycloaddition, trans-stilbene 
We started with dichloroacetylchloride and NEt3, but no reaction was observed and the 
starting material was reisolated unchanged after the reaction. We switched to more 
reactive conditions and employed zinc-metal and trichloracetylchloride166, but with no 
success. Also further activation with phosphorylchloride and zinc-copper-couple as 
metal species did not yield the desired material.167 
Subsequently, we replaced our test system with styrol (Scheme 60, Table 7) and the 
reaction conditions tried earlier, zinc-copper-couple, POCl3, trichloracetylchloride and 
diethylether as solvent,167 afforded the desired product. We were able to isolate the 
desired cyclobutane derivative (280). 
 
Scheme 60: [2+2]-cycloaddition on styrol 
Reagents Solvent T Reaction time Yield 
activated Zn, POCl3, 
trichloroacetylchloride167 
Et2O rt 45 min 90% 
Table 7: Reaction conditions [2+2]-cycloaddition, styrol 
However, the same reaction conditions led to decomposition of the third test system, the 
electron rich trimethoxystyrol (281, Scheme 61, Table 8). 
   62 
MeO
MeO
OMe
MeO
MeO
OMe
conditions
O
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281 282  
Scheme 61: [2+2]-cycloaddition on trimethoxystyrol 
Reagents Solvent T Reaction time Yield 
Zn-Cu (commercially available), 
trichloroacetylchloride167 Et2O rt 2 h decomposition 
activated Zn, POCl3, 
trichloroacetylchloride167 
Et2O rt 2 h decomposition 
Table 8: Reaction conditions [2+2]-cycladdition, trimethoxystyrol 
Against great odds we tried the dichloroketene formation conditions on MOM-protected 
CA-4, but as expected with no success. The only reaction to occur was the cleavage of 
the MOM-group (Scheme 62, Table 9) 
 
Scheme 62: [2+2]-cycloaddition on MOM-protected CA-4 
Reagents Solvent T Reaction time Yield 
Dichloroacetylchloride, 
NEt3 
Et2O 0 C° 24 h 0%; SM reisolated 
Zn, trichloroacetylchloride166 Et2O 0 C° 5 h 0%; SM reisolated 
Zn-Cu, 
trichloroacetylchloride166 THF 0 °C 2 h 0%; SM reisolated 
Zn, POCl3, 
trichloroacetylchloride167 
Et2O 40 °C 3 h 0%; MOM-deprotection 
Zn-Cu, POCl3, 
trichloroacetylchloride167 
Et2O 40 °C 3 h 
0%; MOM-deprotection, 
cis-trans-isomerization 
Table 9: Reaction conditions [2+2]-cycloaddition, MOM-protected CA-4 
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2.5.2. Second approach – Squaric acid 
 
Scheme 63: Retrosynthetic analysis of the squaric acid approach 
The synthetic strategy (Scheme 63) was the incorporation of the two aromatic rings 
(287, 289) at the keto-functionalities of dimethylester of squaric acid (288), followed by 
elimination of two molecules of methanol with concentrated hydrochloric acid of the 
highly substituted cyclobutene derivative (286), as described in the literature, affording 
the diketo-compound (285).168,169 Subsequent decarbonylation as well as hydrogenation 
of the double-bond of the cyclobutenyl-ring should give the desired cyclobutane 
derivative of CA-4 (284). 
O O
MeO OMe
Br
OMe
OMOM
t-BuLi, -78 °C
MeO OMe
O OTBS
OMe
OMOM
Br
MeO
OMe
OMe
t-BuLi, -78 °C
MeO OMe
OTBS
OMe
OMOM
HO
MeO
MeO
MeO
Imidazole,
TBS-Cl
288 250 290
289
292
MeO OMe
O OH
OMe
OMOM
291
65%
30%
 
Scheme 64: Squaric acid approach 
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First, one equivalent of the MOM-protected aromatic derivative (250) was lithiated with 
t-BuLi at -78 °C in diethyl ether, after addition of dimethylsquarate the aromate was 
added, giving the resulting alcohol (290) with acceptable yield.168 The tertiary alcohol 
was protected with TBS-chloride, affording (291).169 But this approach failed at the next 
step. The plan was to repeat the reaction conditions for lithiating the second aromate, 
but we were not able to introduce that at the second keto-functionality of 
dimetylsquarate, affording 292, so this approach was abandoned. 
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3. Biological evaluation 
The biological activity of the compounds prepared within this work was evaluated on two 
human cancer cell lines. The biological activity study was carried out by cooperation 
partners at the University of Szeged. 
HeLa cells are cervical epitheloid carcinoma cells and MCF 7 is a breast carcinoma cell 
line. 
All tested compounds and their assigned numbers are listed in the following table. 
Assay- 
number 
Compound 
Assay- 
number 
Compound 
1643 
 
1649 
 
1644 
 
1650 
 
1645 
 
1651 
 
1646 
 
1652 
MeO
MeO
OMe
OMe
NHBoc
270  
1647 
 
1653 
 
1648 
 
1654 
 
Table 10: Tested compounds 
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3.1. Results – HeLa cells 
The concentration of the assays which were applied on the cell culture was 30 μM. The 
inhibition of cell proliferation within a certain time is investigated. The bars in Scheme 65 
demonstrate that all compounds with just one exception, the alkyne derivative 293 
(assay # 1645) show potent biological activity. When the inhibition of a compound is 
less than 50% at 30 μM it is considered as inactive. It seems very interesting that also 
the alkyne derivatives are active at that concentration. 
 
Scheme 65: HeLa screen 
For more detailed investigations the test was repeated with lower concentration to 
describe the dose-response relationship and the half maximal inhibitory concentration 
(IC50-value).  
The graph in Scheme 66 demonstrates the IC50-value for CA-4 (4, assay # 1647) for 
HeLa cells. 
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Scheme 66: IC50 value for CA-4 (HeLa cells) 
In comparison to the result for CA-4, Scheme 67 shows the IC50-values for the 
cyclopropane derivative (9, assay # 1651) of CA-4 and the appropriate diphosphate 
analog (268, assay # 1654).  
 
Scheme 67: IC50-value for the cyclopropane derivatives 1651 and 1654 (HeLa cells) 
The IC50-concentrations for all tested compounds on HeLa cells are listed in Table 11. 
 
0,0005 μM 
0,028 μM 0,037 μM 
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Assay-number 
Compound- 
number 
Calculated IC50 value [μM] 
HeLa cells 
1643 292 1.54 
1644 248 26.81 
1645 293 >30 
1646 258 0.197 
1647 4 0.0005 
1648 269 1.17 
1649 259 0.246 
1650 266 23.96 
1651 9 0.028 
1652 270 10.07 
1653 267 10.17 
1654 268 0.037 
Table 11: IC50-concentrations, HeLa cells 
3.2. Results – MCF 7 cells 
The same tests as described for HeLa cells were prepared for the MCF 7 cell line. 
Scheme 68 shows the results of the first screening with an assay concentration of 30 
μM. 
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Scheme 68: MCF 7 screen 
The result is very similar in comparison to HeLa cells, all compounds, except compound 
293 (assay # 1645), show potent cytotoxicity against MCF 7 cells. 
Again, the tests were repeated with lower concentrations to determine the IC50-values. 
Scheme 69 presents the IC50-concentration for CA-4 (4, assay # 1647) and in 
comparison Scheme 70 describes the values for the cyclopropane derivative (9, assay # 
1651) and the diphosphate analog of CA-4 (268, assay # 1654). 
 
Scheme 69: IC50 value for CA-4 (MCF 7 cells) 
 
0,0024 μM 
? 1647
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Scheme 70: IC50-value for the cyclopropane derivatives 1651 and 1654 (MCF 7 cells) 
The IC50-values for all tested compounds on MCF 7 cells are listed in Table 12. 
Assay-number 
Compound- 
number 
Calculated IC50 value [μM] 
MCF 7 cells 
1643 292 1.64 
1644 248 25.63 
1645 293 >30 
1646 258 0.269 
1647 4 0.0024 
1648 269 3.85 
1649 259 1.17 
1650 266 14.01 
1651 9 0,102 
1652 270 11.84 
1653 267 10.77 
1654 268 0,297 
Table 12: IC50-concentrations, MCF 7 cells 
0,102 μM 
0,297 μM 
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4. Conclusion and Outlook 
CA-4 is a biologically very active compound by binding to the colchicine binding site 
which lead to the inhibition of microtubule polymerization as well as showing 
antivascular effects by selectively shutting down the tumor blood flow. To avoid the 
disadvantage of rather low in vivo efficiacy resulting from the isomerization of the cis-
stilbene derivative to the thermodynamically more stable trans-isomer, our research 
group started the project for CA-4 analogs synthesis. The incorporation of carbocycles 
with different ring sizes on the connecting carbon-bridge of the natural compound 
prevents the system to undergo cis-trans-isomerization. The synthesis of the 
cyclopropane derivative of CA-4 (9) via the cyclopropanation reaction with 
diazomethane, and further analogs with incorporated moieties for better water solubility 
(268, 273) were achieved within this diploma thesis. In cooperation with the Department 
of Pharmacodynamics and Biopharmacy of the University of Szeged we were able to 
investigate the biological activity against two human cancer cell lines (HeLa and MCF 7) 
of the compounds prepared within this work. 
 
Figure 30: Biologically active compounds synthesized within this work 
Cyclopropanes prepared during this study show almost the same activity as the natural 
product against these two human cancer cell lines and are active in the nanomolecular 
range. According to these excellent results our synthetic considerations were 
successful. The biological evaluations show also great promise relating to our 
continuative work, the synthesis of cyclobutane- and cyclopentane derivatives (10, 295). 
Whereas initial studies towards the synthesis of the cyclobutane derivatives were 
already carried out and are described in this thesis. 
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Figure 31: Cyclobutane- and cyclopentane derivative of CA-4 
The derivatives synthesized within this project also allow to investigate the fine-tuning of 
the dihedral angle of the two aromatic ring systems. Comparison of 3D-studies of the 
carbocyclic compounds the cyclobutyl analog is the most promising compound due to 
the similarity of the dihedral angle to that of the natural product. 
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5. Experimental part 
5.1. General 
Synthetic Methods 
The following general procedures were used in all reactions unless otherwise noted. 
Reaction vessels were dried by repeated heating under vacuum (heat gun) followed by 
purging with dry argon. Oxygen- and moisture sensitive reactions were carried out 
under a slight argon overpressure (balloon) and in dry solvents. Sensitive liquids and 
solutions were transferred by double tipped needle or syringe through rubber septa. All 
reactions were stirred magnetically if not stated otherwise. 
Solvents and Chemicals Purification 
The used solvents and chemicals were, if necessary, purified and dried according to 
common procedures as follows. Dry solvents were stored under an argon atmosphere 
over molecular sieve (4Ǻ).  
Methylene chloride was distilled from P2O5, diethylether (Et2O) and tetrahydrofuran 
(THF) were freshly distilled from sodium/benzophenone under argon; Diisopropylamine 
(DIPA), diisopropylethylamine (DIPEA) and triethylamine (TEA), acetonitrile (MeCN), 
hexane and ethyl acetate were distilled from CaH2; toluene was refluxed over sodium 
and freshly distilled. All other solvents were HPLC grade. 
Thin layer chromatography 
All reactions were monitored using Merck silica gel 60-F254 glass plates. The plates 
were developed with a mixture of hexane/ethyl acetate or toluene/ethyl acetate. Unless 
the compound was colored, UV-active spots were detected at longwave UV (254 nm) or 
shortwave (180 nm). Most plates were additionally treated with the following 
visualization ragent: CAN [H2SO4 (conc., 22 mL), phosphormolybdic acid (20 g), 
Ce(SO4)2 (0.5 g), 378 mL H2O)] 
Column chromatography 
Preparative column chromatography and flash chromatography was performed with 
silica gel 60 from Merck (0.040-0.063 μm, 240-400 mesh). 
Analytic and preperative HPLC 
For HPLC separations on analytical scale module systems from Jasco (PU-980, UV-975 
detector, RI-930 RI detector, 250 x 4 mm column) were used. The adsorbent was 
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Superphere Si 60 (40 μm, Merck) or Nucleosil 50 (4μm, Macherey-Nagel). The 
semipreparative and preparative scale was covered by module systems from Dynamax 
(SD-1 pump, UV-1 UV detector), Knauer (RI detector) and Shimadzu (LC-8A, SPD-20A 
UV/VIS Detector, LC-20AT Bus Module). 
NMR-Spectroscopy 
NMR spectra were recorded either on a Bruker Avance AV 400, DRX 400, or DRX 600 
MHz spectrometer. Unless otherwise stated, all NMR spectra were measured in CDCl3 
solutions and referenced to the residual CDCl3 signal (1H, d=7.26, 13C, d=77.16). All 1H 
and 13C shifts are given in ppm (s = singlet, d = doublet, dd = doublet of doublets, t = 
triplet, q = quartet, m = multiplet, b = broadened signal). Coupling constants J are given 
in Hz. Assignments of proton resonances were confirmed, when possible, by correlated 
spectroscopy (COSY, HSQC, HMBC, TOCSY, NOESY).  
Mass Spectroscopy 
Mass spectra were measured on spectrometers from Micro Mass, Fisions Instrument 
and Trio200. Stated is the kind of ionization - in most cases EI, (Electron Impact); 
occasionally FAB, (Fast Atom Bombardment), - and electron activation energy (in eV). 
HRMS (High Resolution Mass Spectra) were taken with a Finnigan MAT 8230 with a 
resolution of 10000. 
Infrared Spectroscopy 
IR were recorded using a Perkin-Elmer 1600 Series FTIR spectrometer and are 
reported in wave numbers (cm-1). All compounds were measured as a thin film on 
silicon single crystal plate. 
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5.2. Procedures 
2-Methoxyphenyl methanesulfonate (253). 
 
To a solution of guaicol (252, 100.5 mmol, 11.3 mL) and NEt3 (150 mmol, 20.9 mL) in 
100 mL CH2Cl2 was added Ms-Cl (126 mmol, 9.75 mL) dropwise over 5 min (126 mmol, 
9.75 mL) at 0 °C. The reaction mixture was allowed to stir at 0 °C for 90 min and further 
12 hours at r.t. until total consumption of the starting material. The solution was 
quenched with 100 mL water and the organic layer was separated. The aqueous phase 
was extracted with CH2Cl2 (2 x 100 mL) and the combined organic extracts were 
washed with saturated aq. NaHCO3 (3 x 100 mL), water (2 x 150 mL) and brine (2 x 150 
mL). The organic phase was dried over Na2SO4 and the solvent was removed under 
reduced pressure affording 19.8 g (97%) of 253 as yellow oil without further 
purification.150 
Rf 0.38 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.33-7.24 (m, 2H), 7.03-6.95 (m, 2H), 3.90 (s, 3H), 
3.18 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 128.41, 124.75, 121.32, 113.10, 56.13, 38.40. 
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5-Bromo-2-methoxyphenyl methanesulfonate (254). 
 
To a solution of 253 (49 mmol, 10 g) in 25 mL DMF was added NBS (64 mmol, 11.4 g) 
in 25 mL DMF. The reaction mixture was stirred at room temperature until total 
consumption of the starting material (48 h). The reaction was quenched with saturated 
aqueous NH4Cl (200 mL). The resulting solution was diluted with diethyl ether (100 mL), 
the organic layer was separated and the aqueous phase was extracted with diethyl 
ether (4 x 100 mL). The combined organic extracts were washed with water 
(1 x 100 mL) and brine (1 x 100 mL), dried over Na2SO4, and the solvent was removed 
under reduced pressure affording 13.3 g of 254 as white crystals.150 
Rf 0.53 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.38 (d, J = 2.44 Hz, 1H), 7.31 (dd, J = 8.80, 2.44 
Hz, 1H), 6.81 (d, J = 8.8 Hz, 1H), 3.81 (s, 3H), 3.13 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 151.32, 139.02, 131.47, 128.02, 114.59, 112.76, 
56.68, 38.93.  
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5-Bromo-2-methoxyphenol (255). 
 
A THF-solution of LDA (1.5 M, 69.5 mL, 53.4 mmol) was added dropwise to a solution 
of 254 (35.6 mmol, 10 g) in 36 mL THF at 0 °C. After being stirred for 30 min the 
reaction mixture was quenched with 5% aq. HCl. The product was extracted with diethyl 
ether (3 x 100 mL). The etheral extracts were washed successively with water 
(2 x 100 mL) and brine (2 x 100 mL), dried over Na2SO4, and the solvent was removed 
under reduced pressure. The residue was purified by flash chromatography 
(hexanes/ethyl acetate 5:1) affording 255 (6.7 g, 93%) as white crystals.150 
Rf 0.5 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.07 (d, J = 2.27 Hz, 1H), 6.96 (dd, J = 8.59, 2.37 
Hz, 1H), 6.71 (d, J = 8.59 Hz, 1H), 5.63 (s, 1H), 3.87 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 146.67, 146.02, 122.94, 117.99, 113.44, 112.00, 
56.24. 
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4-Bromo-1-methoxy-2-(methoxymethoxy)benzene (250). 
 
To a solution of 255 (9.9 mmol, 2 g) in 10 mL CH2Cl2 at 0 °C was first added DIPEA 
(49.5 mmol, 8.6 mL) and then MOM-Cl (29.7 mmol, 2.3 mL). The reaction mixture was 
allowed to warm to room temperature and was stirred until total consumption of the 
starting material (48 h). The reaction was quenched with aqueous sat. NH4Cl. The 
organic layer was separated and the aqueous layer was extracted with CH2Cl2 
(2 x 10 mL). The combined organic extract was dried over Na2SO4, and the solvent was 
removed under reduced pressure. The residue was purified by flash chromatography 
(hexanes/ethyl acetate 19:1) affording 250 (2.33 g, 95%) as a colorless oil. 
Rf 0.53 (hexanes/ethyl acetate 5:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.29 (d, J = 2.36 Hz, 1H), 7.09 (dd, J = 8.58, 2.36 
Hz, 1H), 6.76 (d, J = 8.58 Hz, 1H), 5.21 (s, 2H), 3.85 (s, 3H), 3.51 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 149.24, 147.43, 125.24, 119.84, 113.16, 112.79, 
95.77, 56.47, 56.22. 
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5-Ethynyl-1,2,3-trimethoxybenzene (251). 
 
To a solution of TMS-diazomethane (6.3 mmol, 3.15 mL) in THF (7 mL) was added n-
BuLi (2.5 M in hexanes, 6 mmol, 2.4 mL) at -78 °C. After the mixture had been stirred 
for 25 min a solution of 251 (5.1 mmol, 1 g) in THF (2.5 mL) was added. After stirring for 
an additional hour at -78 °C the reaction mixture was allowed to warm to r.t. The 
reaction was quenched with aqueous sat. NH4Cl. The aqueous layer was extracted with 
ethyl acetate (2 x 20 mL). The organic layers were dried over Na2SO4 and concentrated 
in vacuo. The residue was purified by flash chromatography (hexanes/ethyl acetate 9:1 
to 5:1) affording 249 (0.89 g, 90%) as light yellow crystals.170 
Rf 0.24 (hexanes/ethyl acetate 9:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 6.73 (s, 2H), 3.85 (s, 9H), 3.03 (s, 1H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 153.21, 139.49, 117.17, 109.55, 83.85, 76.34, 
61.09, 56.30.  
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1,2,3-Trimethoxy-5-((4-methoxy-3-(methoxymethoxy)phenyl)ethynyl)-
benzene (248). 
 
A solution of n-BuLi (2.5 M in hexanes, 4.64 mL, 11.6 mmol) was slowly added to a 
solution of 249 (11.1 mmol, 2.13 g) in 110 mL of the solvent mixture DME/THF in a 10:1 
ratio (freshly distilled, degazed) under argon. After one hour at -78 °C triisopropylborate 
(11.02 mmol, 2.54 mL) was added. After stirring for additional two hours at -78 °C the 
temperature was raised to room temperature over 30 min. At the same time 250 
(8.1 mmol, 2.0 g) and Pd(PPh3)4 (0.081 mmol, 94 mg) were dissolved in 20 mL of the 
solvent mixture DME/THF 10:1, stirred for 10 min at room temperature and the solution 
was added to the reaction mixture of the alkyne.  
After two days refluxing at 90 °C, the reaction mixture was cooled to room temperature 
and quenched with 100 mL water. The aqueous layer was extracted with ethyl acetate 
(3 x 100 mL), the organic phases were collected, dried over Na2SO4 and the solvents 
were removed under reduced pressure. The residue was purified by flash 
chromatography (hexanes/ethyl acetate 19:1) affording 248 (1.63 g, 56%) as slightly 
yellow crystals.146 
Rf 0.3 (hexanes/ethyl acetate 5:1). 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.34 (d, J = 2.02 Hz, 1H), 7.19 (dd, J = 8.38, 2.02 
Hz, 1H), 6.87 (d, J = 8.38 Hz, 1H), 6.76 (s, 2H), 5.25 (s, 2H), 3.91 (s, 3H), 3.89 (s, 6H), 
3.87 (s, 3H), 3.54 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 153.22, 150.31, 146.39, 138.82, 126.42, 119.40, 
118.62, 115.66, 111.71, 108.84, 95.63, 88.51, 88.20, 61.11, 56.42, 56.29, 56.07; 
IR ν 2938 2837 1464 1154 1078 cm-1. 
   81 
(Z)-1,2,3-Trimethoxy-5-(4-methoxy-3-(methoxymethoxy)styryl)-benzene 
(258). 
 
Cyclohexene (5.7 mmol, 0.58 mL) was added to borane-tetrahydrofurane complex (1 M 
in hexanes, 3 mmol, 3 mL) at 0 °C. After stirring for 90 min at this temperature 248 
(0.56 mmol, 200 mg) dissolved in 4 mL THF was added. The reaction mixture was 
stirred at 0 °C until total consumption of the starting material (60 min, TLC), before 
being quenched with 1 mL AcOH. After that 10 mL ethyl acetate were added and the 
mixture was washed with saturated aqueous NaHCO3 (2 x 15 mL), water (2 x 15 mL) 
and brine (1 x 10 mL) before drying over Na2SO4. The solvent was removed under 
reduced pressure and the residue was purified by flash column chromatography 
(hexanes/ethyl acetate, 19:1) affording 161 mg (80%) of 258.153 
Rf 0.4 (hexanes/ethyl acetate 5:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.07 (d, J = 2.05 Hz, 1H), 6.92 (dd, J = 8.42, 2.03 
Hz, 1H), 6.78 (d, J = 8.42 Hz, 1H), 6.50 (s, 2H), 6.46 (dd, J = 18.09, 11.98 Hz, 2H), 5.06 
(s, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 3.70 (s, 6H), 3.41 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 153.07, 149.21, 146.12, 137.21, 133.00, 130.15, 
129.60, 129.15, 123.64, 117.52, 111.50, 106.01, 95.65, 60.95, 56.16, 56.01; 
IR ν 2937 2835 1579 1427 1078 1005 cm-1. 
   82 
(Z)-2-Methoxy-5-(3,4,5-trimethoxystyryl)phenol (CA-4, 4). 
 
To a solution of 258 (0.14 mmol, 50 mg) in 2 mL methanol 0.5 mL 3 M HCl were added. 
The reaction mixture was stirred for 24 h at room temperature. The solution was diluted 
with CH2Cl2. The organic layer was washed with water (2 x 8 mL), dried over Na2SO4, 
and the solvent was removed under reduced pressure. The residue was purified by 
HPLC affording 38 mg (95%) of 4. 171 
Rf 0.37 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 6.92 (d, J = 2.07 Hz, 1H), 6.80 (dd, J = 8.26, 2.07 
Hz, 1 H), 6.73 (d, J = 8.26 Hz, 1H), 6.44 (dd, J = 12.17, 23.67 Hz, 2H), 5.52 (s, 1H), 
3.86 (s, 3H), 3.84 (s, 3H), 3.69 (s, 6H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 153.01, 145.90, 145.39, 137.34, 132.84, 130,80, 
129.62, 129.19, 121.25, 115.19, 110.47, 106.24, 61.06, 56.10, 56.08;  
IR ν 3752 3422 3152 2837 1419 1274 1005 cm-1. 
   83 
1,2,3-Trimethoxy-5-(2-(4-methoxy-3-(methoxymethoxy)phenyl)-
cyclopropyl)benzene (266). 
 
Diethyl ether (15 mL) and 25 mL saturated aq. NaOH were added in a conical flask and 
cooled to 0 °C. To this two phase system N-methyl-N-nitrosourea (8.25 mmol, 850 mg) 
was added affording a yellow solution of diazomethane which was dried over NaOH-
platelets in a second conical flask before adding to a mixture of 258 (0.55 mmol, 
200 mg) and Pd(OAc)2 (0.0275 mmol, 6 mg) in 1 mL ether. The reaction mixture was 
stirred for 3 hours at 0 °C. The solution was filtered and the solvent was removed under 
reduced pressure. The residue was purified by flash chromatography (toluene/ethyl 
acetate, 19:1) affording 113 mg (55%) of 266.165 
Rf 0.29 (hexanes/ethyl acetate 5:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 6.71 (s, 1H), 6.66 (s, 2H), 4.98 (dd, J = 11.62, 6.65 
Hz, 2H), 3.77 (s, 3H), 3.73 (s, 3H), 3.64 (s, 6H), 2.36 (m, 2H), 1.41 (ddd, J = 5.43, 8.78, 
14.06 Hz, 1H), 1.21 (m, 1H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 152.53, 147.93, 146.09, 136.01, 134.49, 131.32, 
123.10, 117.34, 111.30, 106.09, 95.62, 60.82, 55.99, 55.92, 24.18, 23.80, 12.22; 
IR ν 2944, 2838, 1585, 1233, 1124 1003 cm-1. 
   84 
2-Methoxy-5-((3,4,5-trimethoxyphenyl)ethynyl)phenol (293). 
 
Alkyne 248 (50 mg, 0.14 mmol) was dissolved in 2 mL of the solvent mixture 
MeOH:THF in a 1:1 ratio and 15 drops 3 M HCl were added. The reaction mixture was 
stirred at r.t. for 18 h. The solution was diluted with CH2Cl2. The layers were separated 
and the organic phase was washed with water (1 x 10 mL) and brine (1 x 10 mL). The 
organic layer was dried over Na2SO4, and the solvent was removed under reduced 
pressure. The residue was purified by HPLC affording 293 (45 mg, 90%) as colorless 
oil. 
Rf 0.5 (hexanes/ethyl acetate 1:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.09 (d, J = 1.97 Hz, 1H), 7.05 (dd, J = 8.35, 1.97 
Hz, 1H), 6.81 (d, J = 8.35 Hz, 1H), 6.75 (s, 2H), 5.67 (s, 1H), 3.90 (s, 3H), 3.87 (s, 6H), 
3.86 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 153.19, 147.16, 145.51, 138.79, 124.33, 118.65, 
117.64, 116.11, 110.65, 108.86, 88.55, 88.02, 61.08, 56.27, 56.06; 
IR ν 3627, 3418, 2939, 2839, 1463, 1356 cm-1. 
   85 
2-Methoxy-5-((3,4,5-trimethoxyphenyl)ethynyl)aniline (263). 
 
A solution of 249 in 8 mL DMF was added slowly (5 min) to 5-iodo-2-methoxyaniline 
(262, 600 mg, 2.4 mmol), triethylamine (0.4 mL, 2.88 mmol), Pd(PPh3)2Cl2 (50 mg, 
0.072 mmol), and copper iodide (24 mg, 0.12 mmol) in 20 mL DMF. The reaction 
mixture was stirred over night at room temperature. The reaction was quenched with 
water (30 mL). The organic layer was separated and the aqueous phase was extracted 
with ethyl acetate (3 x 20 mL).The combined organic extracts were washed with water 
(1 x 30 mL) and brine (1 x 30 mL), dried over Na2SO4 and the solvent was removed 
under reduced pressure. The residue was purified by flash chromatography 
(hexanes/ethyl acetate 9:1, 1% NEt3) affording 263 (531 mg, 70%) as yellow crystals.156  
Rf 0.32 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 6.81 (d, J = 8.33 Hz, 1H), 6.78 (s, 3H), 6.73 (dd, J = 
8.33, 2.02 Hz, 1H), 4.87 (s, 2H), 3.82 (s, 6H), 3.79 (s, 3H), 3.68 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 152.89, 146.92, 138.06, 137.81, 119.92, 118.05, 
115.87, 114.28, 110.49, 108.51, 89.46, 87.16, 60.11, 55.97, 55.31; 
IR ν 3673, 3370, 2936, 1575, 1409, 1173 cm-1. 
   86 
2-Methoxy-5-(2-(3,4,5-trimethoxyphenyl)cyclopropyl)phenol (9). 
 
266 (448 mg, 1.2 mmol) was dissolved in 10 mL of a solvent-mixture of MeOH/THF in a 
1:1 ratio and 202 μL 3 M HCl were added. The reaction mixture was stirred at room 
temperature for 18 hours. The solution was diluted with CH2Cl2. The layers were 
separated and the organic phase was washed with water (2 x 20 mL). The organic layer 
was dried over Na2SO4 and the solvent was removed under reduced pressure. The 
residue was purified by HPLC affording 9 (269 mg, 68%) as colorless oil. 
Rf 0.38 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 6.66 (d, J = 2.26 Hz, 1H), 6.62 (d, J = 8.32 Hz, 1H), 
6.46 (dd, J = 8.32, 2.26 Hz, 2H), 6.12 (s, 2H), 5.43 (s, 1H), 3.80 (s, 3H), 3.75 (s, 3H), 
3.65 (s, 6H), 2.40 (m, 1H), 2.31 (m, 1H), 1.41 (m, 1H), 1.21 (m, 1H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 152.55, 145.19, 144.89, 136.08, 134.76, 131.68, 
120.78, 115.82, 110.31, 105.98, 60.95, 56.11, 56.03, 24.22, 24.10, 12.16; 
IR ν 3413, 2937, 2838, 1737, 1514, 1416, 1007 cm-1. 
   87 
(Z)-2-Methoxy-5-(3,4,5-trimethoxystyryl)aniline (264). 
MeO
MeO
MeO
OMe
NH2
MeO
MeO
OMe
OMe
NH2
Pd/CaCO3, H2
263 264  
To a solution of catalyst (Pd/CaCO3, 0.032 mmol, 3.4 mg) in 2 mL ethyl acetate were 
added three drops of quinoline and 400 μL of cyclohexene. The solution was stirred for 
one hour at room temperature. Alkyne 263 (100 mg, 0.32 mmol) was dissolved in 1 mL 
ethyl acetate and was added to the reaction mixture. The solution was exposed to H2 
until total consumption of the starting material (3 h). The reaction mixture was filtered 
and the solvent was removed under reduced pressure. The residue was purified by 
flash chromatography (toluene/ethyl acetate 19:1, 1% NEt3) affording 264 (84 mg, 83%) 
as a yellow oil. 
Rf 0.27 (toluene/ethyl acetate 5:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 6.93 (d, J = 8.27 Hz, 1H), 6.90 (s, 3H), 6.85 (dd, J = 
8.02, 2.02 Hz, 1H), 4.99 (s, 2H), 3.92 (s, 6H), 3.92 (s, 6H), 3.91 (s, 3H), 3.80 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 154.14, 148.16, 139.30, 139.05, 121.16, 119.29, 
117.11, 115.52, 111.73, 109.75, 90.70, 88.40, 61.35, 57.21, 56.56; 
IR ν 3469, 3371, 2936, 1613, 1453, 1326, 1028 cm-1. 
   88 
Tert-butyl 2-methoxy-5-((3,4,5-trimethoxyphenyl)ethynyl)-phenylcarbamate 
(294). 
 
To a stirred solution of 293 (300 mg, 0.96 mmol) in 10 mL of a solvent mixture THF/H2O 
in a 1:1 ratio was added K2CO3 (794 mg, 5.76 mmol) at room temperature. After 10 min 
Boc2O was added (838 mg, 3.84 mmol). The reaction mixture was stirred for two days 
at 60 °C. The reaction was quenched with 5% aqueous HCl. The two layers were 
separated and the aqueous phase was extracted with ethyl acetate (3 x 15 mL). The 
combined organic extracts were washed with water (1 x 20 mL) and brine (1 x 20 mL) 
and the solvent was removed under reduced pressure. The residue was purified by 
flash chromatography (hexanes/ethyl acetate 9:1), affording 294 as a colorless foam 
(356 mg, 90%).172 
Rf 0.58 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 8.32 (s, 1H), 7.16 (dd, J = 8.34, 2.02 Hz, 1H), 7.09 
(s, 1H), 6.81 (d, J = 8.34 Hz, 1H), 6.75 (s, 2H), 3.89 (s, 3H), 3.88 (s, 6H), 3.86 (s, 3H), 
1.54 (s, 9H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 153.19, 152.77, 147.69, 138.66, 128.25, 126.02, 
121.09, 118.89, 116.03, 109.94, 108.83, 88.94, 88.02, 80.75, 61.11, 56.31, 55.91, 
28.51; 
IR ν 3436, 2938, 2839, 1726, 1527, 1128 cm-1. 
 
   89 
Dibenzyl-2-methoxy-5-(2-(3,4,5-trimethoxyphenyl)-cyclopropyl)-phenyl 
phosphate (9). 
 
A solution of 9 (220 mg, 0.67 mmol) and CCl4 (648 μL, 6.7 mmol) in 4 mL acetonitrile 
was cooled to -10 °C and stirred for 10 min. Then DIPEA (228 μL, 1.34 mmol) and 
DMAP (8 mg, 0.067 mmol) were added. After one minute dibenzylphosphite (221 μL, 
1 mmol) was added slowly and the mixture was stirred for additional 3 hours at -10 °C. 
After total consumption of the starting material the reaction was quenched with 0.5 M 
aqueous KH2SO4 solution. The two layers were separated and the aqueous phase was 
extracted with ethyl acetate (3 x 15 mL). The combined organic extracts were washed 
with water (1 x 20 mL) and brine (1x 20 mL), and the solvents were removed under 
reduced pressure. The residue was purified by column chromatography (hexanes/ethyl 
acetate 3:1), affording 267 as a colorless oil (265 mg, 67%).91 
Rf 0.44 (hexanes/ethyl acetate 1:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.35-7.28 (m, 10H), 7.04 (s, 1H), 6.65 (s, 2H), 6.09 
(s, 2H), 5.16-5.05 (m, 4H), 3.72 (s, 3H), 3.68 (s, 3H), 3.62 (s, 6H), 2.41-2.29 (m, 2H), 
1.45-1.37 (m, 1H), 1.22-1.14 (m, 1H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 152.63, 148.91*, 148.86, 139.29, 139.22, 136.13, 
135.95*, 135.87, 134.33, 131.33, 128.63, 128.57, 127.99, 122.83*, 122.81, 112.26, 
105.0, 69.91, 69.85, 60.89, 56.05, 24.32, 23.70, 12.18; 
IR ν 2938, 2838, 1586, 1378, 1234, 1183, 1082 cm-1. 
 
*) denotes rotamer 
   90 
(Z)-Dibenzyl 2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl phosphate (259). 
 
A solution of 4 (110 mg, 0.35 mmol) and CCl4 (338 μL, 3.5 mmol) in 3 mL acetonitrile 
was cooled to -10 °C and stirred for 10 min. Then DIPEA (118 μL, 0.7 mmol) and DMAP 
(4 mg, 0.035 mmol) were added. After one minute dibenzylphosphite (116 μL, 
0.53 mmol) was added slowly and the mixture was stirred for an additional 3 hours at -
10 °C. After total consumption of the starting material the reaction was quenched with 
0.5 M aqueous KH2SO4 solution. The two layers were separated and the aqueous 
phase was extracted with ethyl acetate (3 x 10 mL). The combined organic extracts 
were washed with water (1 x 15 mL) and brine (1 x 15 mL), and the solvents were 
removed under reduced pressure. The residue was purified by column chromatography 
(hexanes/ethyl acetate 3:1), affording 259 as a colorless oil (115 mg, 57%).91 
Rf 0.44 (hexanes/ethyl acetate 1:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.38-7.27 (m, 10H), 7.18-7.14 (m, 1H), 7.07 (d, J = 
8.32 Hz, 1H), 6.79 (d, J = 8.32, Hz, 1H), 6.49 (s, 2H), 6.43 (dd, J = 18.89, 12.17 Hz, 
2H), 5.16-5.10 (m, 4H), 3.80 (s, 3H), 3.77 (s, 3H), 3.68 (s, 6H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 153.06, 149.93*, 149.88, 139.62*, 139.55, 137.34, 
135.83, 135.76, 132.54, 130.27, 129.76, 128.63, 128.60, 128.55, 127.95, 126.65, 
122.30*, 122.27, 112.39, 106.05, 69.87, 69.81, 60.94, 56.05, 56.02; 
IR ν 2938, 2838, 1579, 1279, 1127, 999 cm-1. 
 
*) denotes rotamer 
   91 
Sodium (Z)-2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl phosphate (6). 
 
A mixture of 259 (100 mg, 0.17 mmol) and sodium iodide (99 mg, 0.66 mmol) in 
anhydrous acetonitrile was stirred at 0 °C and TMS-Br (86 μL, 0.66 mmol) was added 
dropwise. The reaction mixture was stirred for 5 min at that temperature before it was 
quenched with water and extracted with ethyl acetate. The combined organic layers 
were dried over Na2SO4, filtered and the solvent was removed under reduced pressure. 
The residue was purified by flash column chromatography (CH2Cl2/MeOH 3:1, 1% 
AcOH) affording 30 mg (48%) of the free phosphorous acid. The free acid was 
dissolved in 1 mL MeOH and sodium methanolate (8 mg, 0.15 mmol) was added. The 
reaction mixture was stirred for 5 min, afterwards the solvent was removed under 
reduced pressure affording 6 (33 mg, 94%) as a white solid.  
1H NMR (free phosphorus acid, 400 MHz, MeOD) δ [ppm] 7.27 (s, 1H), 7.01 (d, J = 8.53 
Hz, 1H), 6.92 (d, J = 8.53 Hz, 1H), 6.55 (s, 2H), 6.48 (dd, J = 18.45, 12.17 Hz, 2H), 3.82 
(s, 3H), 3.74 (s, 3H), 3.66 (s, 6H). 
   92 
(Z)-1,2,3-Trimethoxy-5-(4-methoxy-3-(methoxymethoxy)styryl)-benzene 
(258). 
 
To a solution of catalyst (Pd/CaCO3, 0.14 mmol, 15 mg) in 10 mL ethyl acetate were 
added 10 drops of quinoline and 3 mL of cyclohexene. The solution was stirred for one 
hour at room temperature. Alkyne 248 (500 mg, 1.4 mmol) was dissolved in 5 mL ethyl 
acetate and was added to the reaction mixture. The solution was exposed to H2 until 
total consumption of the starting material (3 h). The reaction mixture was filtered and the 
solvent was removed under reduced pressure. The residue was purified by flash 
chromatography (toluene/ethyl acetate 19:1) affording 258 (806 mg, 81%) as colorless 
oil. 
Rf 0.4 (toluene/ ethyl acetate 5:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.07 (d, J = 2.05 Hz, 1H), 6.92 (dd, J = 8.42, 2.03 
Hz, 1H), 6.78 (d, J = 8.42 Hz, 1H), 6.50 (s, 2H), 6.46 (dd, J = 18.09, 11.98 Hz, 2H), 5.06 
(s, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 3.70 (s, 6H), 3.41 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 153.07, 149.21, 146.12, 137.21, 133.00, 130.15, 
129.60, 129.15, 123.64, 117.52, 111.50, 106.01, 95.65, 60.95, 56.16, 56.01; 
IR ν 2937 2835 1579 1427 1078 1005 cm-1. 
   93 
3,4-Dimethoxycyclobut-3-ene-1,2-dione (288). 
 
293 (2 g, 17.5 mmol) in 156 mL methanol was refluxed for 72 hours. The solvent was 
removed under reduced pressure. The residue was purified by flash chromatography 
(hexanes/ethyl acetate 2:1) affording 288 (1.05 g, 42%) as white crystals.173 
Rf 0.5 (hexanes/ethyl acetate 1:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 4.37 (s, 6H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 189.28, 184.60, 61.12. 
   94 
4-Hydroxy-2,3-dimethoxy-4-(4-methoxy-3-(methoxymethoxy)-
phenyl)cyclobut-2-enone (290). 
 
The aromatic fragment 287 (951 mg, 3.85 mmol) was dissolved in 15 mL diethyl ether. 
The reaction mixture was cooled to -78 °C and t-BuLi (1.7 M solution, 8.05 mmol, 
4.7 mL) was added. The resulting mixture was stirred for 30 min. The solution of the 
lithiated aromate was transferred via syringe to a solution of dimethyl squarate (288, 
500 mg, 3.5 mmol) in 5 mL of the solvent mixture diethyl ether/THF in a 1:1 ratio at -
78 °C. The reaction mixture was stirred over night and was allowed to warm to room 
temperature. The reaction was quenched with sat. NH4Cl, was extracted with ethyl 
acetate and the solvents were removed under reduced pressure. The residue was 
purified by flash chromatography (hexanes/ethyl acetate 9:1) affording 290 (704 mg, 
65%) as colorless oil.168 
Rf 0.33 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 6.76 (d, J = 5.84 Hz, 1H), 6.74 (s, 1H), 6.45 (dd, J = 
8.68, 2.88 Hz, 1H), 6.01-5.49 (bs, 1H), 5.19 (s, 2H), 3.81 (s, 3H), 3.50 (s, 3H), 2.95 (s, 
3H), 2.88 (s, 3H). 
   95 
Sodium 2-methoxy-5-(2-(3,4,5-trimethoxyphenyl)cyclopropyl)-phenyl 
phosphate (268). 
 
To a mixture of 267 (40 mg, 0.07 mmol) and NaI (42 mg, 0.28 mmol) in anhydrous 
acetonitrile was added TMS-Cl (35 μL, 0.28 mmol) dropwise at room temperature. The 
reaction mixture was stirred for 3 hours, quenched with water and extracted with ethyl 
acetate. The organic layers were combined and the solvent was removed under 
reduced pressure. The residue was purified by flash chromatography (CH2Cl2/MeOH 
5:1, 1% AcOH) affording the free phosphorous acid. The free acid was dissolved in 1 
mL MeOH and sodium methanolate (1.2 mg, 0.023 mmol) was added. The reaction 
mixture was stirred for 5 min, afterwards the solvent was removed under reduced 
pressure affording 268 (10 mg, 32%) as a white solid. 154  
Rf 0.1 (CH2Cl2/MeOH 3:1, 1% AcOH). 
1H NMR (400 MHz, D20) δ [ppm] 7.39 (s, 1H), 6.82 (d, J=8.56 Hz, 1H), 6.83 (dd, J=8.56, 
2,05 Hz, 1H), 6.42 (s, 2H), 3.79 (s, 3H), 3.73 (s, 6H), 3.70 (s, 3H), 2.63-2.53 (m, 1H), 
2.52-2.44 (m, 1H), 1.53-1.44 (m, 2H). 
   96 
(Z)-tert-butyl 2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl-carbamate (269). 
 
To a solution of catalyst (Pd/CaCO3, 0.097 mmol, 10 mg) in 4.5 mL ethyl acetate were 
added six drops of quinoline and 6 mL of cyclohexene. The suspension was stirred for 
one hour at room temperature. Alkyne 294 (400 mg, 0.97 mmol) was dissolved in 2 mL 
ethyl acetate and was added to the reaction mixture. The solution was exposed to H2 
until total consumption of the starting material (3 h). The reaction mixture was filtered 
and the solvent was removed under reduced pressure. The residue was purified by 
flash chromatography (toluene/ethyl acetate 19:1 to 9:1, 1% NEt3) affording 269 (1.68 g, 
88%) as a yellow oil. 
Rf 0.51 (toluene/ethyl acetate 9:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 8.08 (s, 1H), 7.25 (s, 1H), 6.92 (dd, J = 8.58, 2.02 
Hz, 1H), 6.69 (d, J = 8.58 Hz, 1H), 6.53 (s, 2H), 6.46 (dd, J = 39.53, 12.06 Hz, 2H), 3.84 
(s, 6H), 3.69 (s, 6H), 1.50 (s, 9H); 
13C NMR (400 MHz, CDCl3) δ 153.0, 152.79, 146.74, 137.94, 133.04, 130.34, 130.07, 
129.05, 128.37, 128.04, 123.10, 123.10, 118.96, 109.64, 106.25, 80.07, 61.04, 56.05, 
28.47; 
IR ν 3437, 2975, 1727, 1579, 1366, 1127, 1050 cm-1. 
   97 
Tert-butyl-2-methoxy-5-(2-(3,4,5-trimethoxyphenyl)-cyclopropyl)-phenyl-
carbamate (270). 
 
Diethyl ether (25 mL) and 50 mL saturated aq. NaOH were added in a conical flask and 
cooled to 0 °C. To this two phase system N-methyl-N-nitrosourea (24 mmol, 2.47 g) was 
added affording a yellow solution of diazomethane which was dried over NaOH-platelets 
in a second conical flask before adding to a mixture of 269 (1.2 mmol, 500 mg) and 
Pd(OAc)2 (0.12 mmol, 27 mg) in 3 mL diethyl ether. The reaction mixture was stirred for 
20 min at 0 °C. The solution was filtered and the solvent was removed under reduced 
pressure. Afterwards the described procedure was repeated to afford complete 
conversion. The residue was purified by HPLC (toluene/ethyl acetat 19:1) affording 
300 mg (58%) of 270 as a yellow oil.165 
Rf 0.47 (toluene/ethyl acetate 9:1); 
1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 6.97 (s, 1H), 6.56 (d, J = 8.36 Hz, 1H), 6.50 
(dd, J = 8.36, 1.90 Hz, 1H), 6.18 (s, 2H), 3.74 (s, 3H), 3.73 (s, 3H), 3.66 (s, 6H), 2.48-
2.38 (m, 1H), 2.37-2.27 (m, 1H), 1.50 (s, 9H), 1.42-1.28 (m, 2H); 
13C NMR (400 MHz, CDCl3) δ 152.70, 152.44, 145.69, 135.87, 134.70, 130.87, 127.49, 
122.59, 119.12, 109.39, 106.05, 80.13, 60.85, 55.94, 55.71, 28.43, 24.34, 24.32, 11.57; 
IR ν 3436, 2975, 1724, 1509, 1367, 1156, 1049 cm-1. 
   98 
2-Methoxy-5-(2-(3,4,5-trimethoxyphenyl)cyclopropyl)aniline (271). 
 
270 (300 mg, 0.7 mmol) was dissolved in 6 mL acetonitrile, transferred in a microwave 
reaction vessel and 1.5 g silica gel were added. The reaction mixture was placed in the 
microwave for 1 h at 180 °C (after 30 min the progress of the reaction was verified by 
TLC). The silica gel was filtered over a suction filter and was washed successfully with 
methanol. The solvent was removed under reduced pressure and the residue was 
purified by flash column chromatography (toluene/ethyl acetate 19:1) affording 190 mg 
(83%) of 271 as a yellow oil. 
Rf 0.24 (toluene/ethyl acetate 5:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 6.57 (d, J = 8.08 Hz, 1H), 6.43 (d, J = 2.00 Hz, 1H), 
6.38 (dd, J = 8.08, 2.00 Hz, 1H), 6.12 (s, 2H), 3.76 (s, 3H), 3.77 (s, 3H), 3.64 (s, 6H), 
2.44-2.33 (m, 1H), 2.32-2.22 (m, 1H), 1.46-1.39 (m, 1H), 1.20-1.12 (m, 1H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 152.48, 145.85, 135.95, 135.71, 135.20, 130.93, 
119.27, 116.53, 110.13, 105.86, 60.92, 55.99, 55.68, 24.17, 23.92, 12.62; 
IR ν 3369, 2934, 1719, 1465, 1183, 1008 cm-1. 
   99 
(2R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(2-methoxy-5-(2-(3,4,5-
trimethoxyphenyl)cyclopropyl)phenylamino)-3-oxopropyl acetate (272). 
 
To a solution of 271 (200 mg, 0.3 mmol) in 6 mL anhydrous DMF, DIC (283 μL, 
1.83 mmol), Fmoc(Ac)-serine (676 mg, 1.83 mmol), and HOBt.H2O (218 mg, 
1.83 mmol) were added, and the resulting reaction mixture was stirred for 16 h at room 
temperature. The reaction was quenched with water and extracted with diethyl ether 
(3 x 20 mL). The combined organic layers were subsequently washed with water 
(2 x 20 mL), dried over Na2SO4 and the solvent was removed under reduced pressure. 
The crude product was purified by flash column chromatography (toluene/ethyl acetate 
19:1 to 5:1) to give 272 (315 mg, 76%) as a white solid.159 
Rf 0.1 (hexanes/ethyl acetate 2:1), 
1H NMR (400 MHz, CDCl3) δ [ppm] 8.34 (s, 1H), 8.19 (d, J = 7.08 Hz, 1H), 7.77 (d, J = 
7.32 Hz, 2H), 7.60 (d, J = 7.32 Hz, 2H), 7.44-7.27 (m, 4H), 6.60 (s, 2H), 6.18 (d, J = 
4.80 Hz, 2H), 5.69 (bs, 1H), 4.62 (bs, 1H), 4.54- 4.40 (m, 3H), 4.35-4.21 (m, 2H), 3.73 
(s, 3H), 3.72 (s, 3H), 3.66 (s, 3H), 3.65 (s, 3H), 2.50-2.31 (m, 2H), 2.08 (s, 3H), 1.47-
1.37 (m, 1H), 1.31-1.29 (m, 1H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 170.57, 166.25, 152.39, 146.19, 143.55, 141.29, 
135.83, 134.32*, 134.26, 131.01*, 130.99, 127.80, 127.10, 126.09, 124.96, 124.57, 
121.02*,120.76, 120.03*, 120.02, 109.41, 106.01*, 105.90, 67.48, 63.89, 60.73, 55.85, 
55.73, 47.08, 24.44*, 24.31, 24.06*, 24.00, 20.67, 11.45; 
IR ν 3325, 2943, 2838, 1741, 1234, 1030 cm-1. 
 
*) denotes rotamer 
   100 
(2R)-2-Amino-3-hydroxy-N-(2-methoxy-5-(2-(3,4,5-trimethoxyphenyl)-
cyclopropyl)phenyl)propanamide. 
 
The protected cyclopropyl derivative (272, 200 mg, 0.29 mmol) was dissolved in 4 mL of 
a solvent mixture of CH2Cl2/MeOH in a 1:1 ratio and 290 μL of an aqueous solution of 
2 M NaOH (0.58 mmol) were added to this biphasic mixture. The reaction mixture was 
stirred for 1 h and the reaction was diluted with water and extracted with CH2Cl2 
(8 x 15 mL). The combined organic layers were dried over Na2SO4, filtered and the 
solvent was removed in vacuo. The residue was purified by flash chromatography 
(CH2Cl2/MeOH 19:1) affording 110 mg (92%) of the seine derivative as a colorless 
oil.159 
Rf 0.63 (CH2Cl2/MeOH 5:1) 
1H NMR (400 MHz, CDCl3) δ [ppm] 9.75 (s, 1H), 8.19 (d, J = 20.87 Hz, 1H), 6.64 -6.58 
(m, 2H), 6.20-6.16 (m, 2H), 3.98-3.90 (m, 1H), 3.79 (s, 3H), 3.77-3.74 (m, 1H), 3.73 (s, 
3H), 3.66 (s, 3H), 3.65 (s, 3H), 3.56-3.50 (m, 1H), 2.49-2.29 (m, 2H), 2.11 (bs, 3H), 
1.45-1.36 (m, 1H), 1.36-1.28 (m, 1H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 171.68*, 171.63, 152.32, 146.56*, 146.52, 135.74, 
134.50*, 134.41, 130.80*, 130.75, 126.45, 124.27*, 124.09, 120.63*, 120.22, 109.40*, 
109.36, 106.14*, 105.94, 65.46*, 65.40, 60.74, 56.60*, 56.58, 55.85, 55.72, 24.37*, 
24.18, 24.05*, 23.96, 11.51*, 11.47; 
IR ν 3306, 2938, 1510, 1234, 1027 cm-1. 
 
*) denotes rotamer 
   101 
(R,Z)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(2-methoxy-5-(3,4,5-
trimethoxystyryl)phenylamino)-3-oxopropyl acetate (265). 
 
To a solution of 264 (200 mg, 0.63 mmol) in 6 mL anhydrous DMF, DIC (293 μL, 
1.89 mmol), Fmoc(Ac)-serine (698 mg, 1.89 mmol) and HOBt.H2O (225 mg, 1.89 mmol) 
were added and the resulting reaction mixture was stirred for 16 h at room temperature. 
The reaction was quenched with water and extracted with diethyl ether (3 x 20 mL). The 
combined organic layer was washed successfully with water (2 x 20 mL), dried over 
Na2SO4 and the solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography (toluene/ethyl acetate 19:1 to 9:1) to give 265 
(295 mg, 70%) as a white solid.159 
Rf 0.1 (tolene/ethyl acetate 5:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 8.40 (s, 1H), 8.30 (d, J = 1.76 Hz, 1H), 7.76 (d, J = 
7.56 Hz, 2H), 7.60 (d, J = 6.56 Hz, 2H), 7.44-7.36 (m, 2H), 7.36-7.27 (bs, 2H), 7.03 (dd, 
J = 8.60, 1.76 Hz, 1H), 6.71 (d, J = 8.60 Hz, 1H), 6.51 (s, 2H), 6.48 (dd, J=21.44, 12.16 
Hz, 2H), 5.83-5.68 (bs, 1H), 4.69-4.57 (bs, 1H), 4.55-4.41 (m. 3H), 4.38-4.28 (m, 1H), 
4.28-4.21 (m, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.69 (s, 6H), 2,09 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 170.76, 166.54, 153.04, 147.28, 143.77, 143.68, 
141.43, 137.30, 132.86, 130.34, 129.57, 129.47, 127.94, 127.24, 126.69, 125.17, 
125.09, 121.02, 120.17, 109.75, 106.17, 67.64, 64.05, 61.00, 56.04, 55.00, 54.87, 
20.83; 
IR ν 3306, 2938, 1674, 1510, 1463, 1126 cm-1. 
   102 
(R,Z)-2-Amino-3-hydroxy-N-(2-methoxy-5-(3,4,5-trimethoxystyryl)-phenyl)-
propanamide. 
 
265 (200 mg, 0.3 mmol) was dissolved in 4 mL of a solvent mixture of CH2Cl2/MeOH in 
a 1:1 ratio and 0.3 mL of an aqueous solution of 2 M NaOH (0.6 mmol) was added to 
this biphasic mixture. The reaction mixture was stirred for 1 h and the reaction was 
diluted with water and extracted with CH2Cl2 (8 x 15 mL). The combined organic layers 
were dried over Na2SO4, filtered and the solvent was removed in vacuo. The residue 
was purified by flash chromatography (CH2Cl2/MeOH 19:1) affording 73 mg (61%) of 
the serine derivative as a colorless oil.159 
Rf 0.72 (CH2Cl2/MeOH 5:1); 
1H NMR (400 MHz, CDCl3) δ [ppm] 9.84 (s, 1H), 8.36 (d, J = 2.04 Hz, 1H), 7.01 (dd, J = 
8.32, 2.04 Hz, 1H), 6.72 (d, J = 8.32 Hz, 1H), 6.51 (s, 2H), 6.48 (dd, J = 31.59, 12.14 
Hz, 2H), 4.01-3.94 (m, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.82-3.75 (m, 1H), 3.69 (s, 6H), 
3.60-3.55 (m, 1H), 2.97-2.36 (bs, 1H), 1.95-1.51 (bs, 2H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 171.94, 153.03, 147.75, 130.00, 130.22, 129.86, 
129.25, 127.07, 124.78, 120.72, 109.72, 109.78, 106.24, 65.68, 61.04, 56.75, 56.07, 
56.02; 
IR ν 3305, 2935, 1580, 1325, 1123, 1026 cm-1. 
   103 
(R,Z)-2-Amino-3-hydroxy-N-(2-methoxy-5-(3,4,5-trimethoxystyryl)-phenyl)-
propanamide hydrochloride (AVE8062, 7). 
 
The serine derivative (20 mg, 0.05 mmol) was dissolved in 0.3 mL of methanol and 
50 μL 4 M HCl in dioxane were added. The resulting reaction mixture was stirred for 
10 min. The solvent was removed under reduced pressure affording the desired 
hydrochloride 7 as a light yellow solid (20 mg, 91%).159 
1H NMR (400 MHz, MeOD) δ [ppm] 1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 2.04, 1H), 
7.07 (dd, J = 8.46, 2.04, 1H), 6.96 (d, J = 8.46, 1H), 6.55 (s, 2H), 6.50 (dd, J = 17.43, 
12.13, 2H), 4.21 (m, 1H), 4.02-3.95 (m, 1H), 3.95-3.84 (m, 5H), 3.75 (s, 3H), 3.73-3.62 
(m, 8H); 
13C NMR (400 MHz, MeOD) δ [ppm] 13C NMR (400 MHz, CDCl3) δ 166.63, 154.19, 
150.65, 138.25, 134.35, 131.24, 130.48, 130.34, 127.54, 127.30, 123.86, 
111.73,107.42, 61.77, 61.19, 56.47, 56.43*, 56.39; 
IR ν 3233, 2938, 1694, 1548, 1326, 1126, 1026 cm-1. 
   104 
(2R)-2-Amino-3-hydroxy-N-(2-methoxy-5-(2-(3,4,5-trimethoxyphenyl)-
cyclopropyl)phenyl)propanamide hydrochloride (273). 
MeO
MeO
OMe
OMe
N
H
O
NH2
OH
MeO
MeO
OMe
OMe
N
H
O
NH2HCl
OH
4 M HCl
273  
The serine derivative (20 mg, 0.05 mmol) was dissolved in 0.3 mL methanol and 50 μL 
4 M HCl in dioxane were added. The resulting reaction mixture was stirred for 10 min. 
The solvent was removed under reduced pressure affording the desired hydrochloride 
273 as a light yellow solid (21 mg, 91%).159 
1H NMR (400 MHz, MeOD) δ [ppm] 1H NMR (400 MHz, CDCl3) δ 7.81 (s, 1H), 6.85-6.78 
(m, 2H), 6.21 (d, J = 8.78 Hz, 2H), 4.20-4.14 (m, 1H), 4.0-3.93 (m, 1H), 3.92-3.78 (m, 
4H), 3.68-3.61 (m, 12H), 2.51-2.35 (m, 2H), 1.46-1.31 (m, 2H); 
13C NMR (400 MHz, MeOD) δ [ppm] 13C NMR (400 MHz, CDCl3) δ 166.50, 153.57, 
149.46, 149.43*, 136.33, 136.29*, 136.26, 136.23*, 131.84, 131.78*, 127.31, 127.22*, 
126.93, 124.15, 124.09*, 111.30, 111.28*, 107.23, 107.05*, 61.75, 61.05, 56.44*, 56.38, 
25.15, 25.11*, 25.06, 24.99*, 11.76, 11.66*; 
IR ν 3270, 2943, 1688, 1509, 1325, 1182, 1027 cm-1. 
 
*) denotes rotamer 
   105 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-hydroxy-propanoic acid. 
 
L-Serine (2.0 g, 19 mmol) and NaHCO3 (4.0 g, 47.5 mmol) were dissolved in 40 mL 
H2O and cooled to 0 °C. Fmoc-Cl (4.9 g, 19 mmol) was dissolved in 40 mL dioxane and 
added dropwise to the aqueous solution. After addition was completed the ice bath was 
removed and the solution was stirred for 48 h. The solvent was removed under reduced 
pressure. The resulting suspension was diluted with H2O, washed with Et2O 
(2 x 100 mL) and the aqueous phase was acidified with 1 M citric acid to pH 3.5. The 
aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic 
phases were dried over Na2SO4 and the solvent was removed under reduced pressure. 
The crude product was recrystallized from CH2Cl2-hexanes affording 4.57 g (65%) of 
the Fmoc-protected serine as a white solid.174 
Rf 0.68 (CH2Cl2/MeOH 3:1, 1% AcOH) 
1H NMR (400 MHz, MeOD) δ [ppm] 7.82-7.76 (m, 2H), 7.72-7.58 (m, 2H), 7.42-7.35 (m, 
2H), 7.34-7.27 (m, 2H), 4.46-4.19 (m, 4H), 3.96-3.76 (m, 2H); 
13C NMR (400 MHz, MeOD) δ [ppm] 173.76, 158.57, 145.17, 142.53, 128.75, 128.14, 
126.26, 126.20*, 120.88, 68.15, 63.09, 57.71, 48.30. 
   106 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-acetoxy-propanoic acid. 
 
Fmoc protected serine (2.58 g, 7.9 mmol) was added slowly to 8.4 mL (118.5 mmol) of 
acetyl chloride. The suspension was stirred for two hours at room temperature. 
Afterwards the excess of acetylchloride was removed under reduced pressure. The 
crude product was recrystallized from CH2Cl2 affording 2.68 g (92%) of the Fmoc- and 
acetate-protected serine as a white solid.175 
Rf 0.9 (CH2Cl2/MeOH 3:1, 1% AcOH); 
1H NMR (400 MHz, CDCl3) δ [ppm] 7.77 (d, J = 7.56 Hz, 2H), 7.50 (d, J = 7.08 Hz, 2H), 
7.45-7.37 (m, 2H), 7.36-7.28 (m, 2H), 4.76-4.64 (m, 1H), 4.60-4.36 (m, 4H), 4.29-4.20 
(m, 1H), 2.09 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ [ppm] 173.41, 170.86, 156.12, 143.83, 141.48, 127.96, 
127.26, 125.18, 120.19, 67.58, 63.99, 53.34, 47.24, 20.83. 
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Abstract 
CA-4 is a biologically very active compound by binding to the colchicine binding site 
which lead to the inhibition of microtubule polymerization as well as showing 
antivascular effects by selectively shutting down the tumor blood flow. To avoid the 
disadvantage of rather low in vivo efficiacy resulting from the isomerization of the cis-
stilbene derivative to the thermodynamically more stable trans-isomer, our research 
group started the project for CA-4 analogs synthesis. The incorporation of carbocycles 
with different ring sizes on the connecting carbon-bridge of the natural compound 
prevents the system to undergo cis-trans-isomerization. The synthesis of the 
cyclopropane derivative of CA-4 (9) via the cyclopropanation reaction with 
diazomethane, and further analogs with incorporated moieties for better water solubility 
(268, 273) were achieved within this diploma thesis. In cooperation with the Department 
of Pharmacodynamics and Biopharmacy of the University of Szeged we were able to 
investigate the biological activity against two human cancer cell lines (HeLa and MCF 7) 
of the compounds prepared within this work. 
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Zusammenfassung 
Der Naturstoff Combretastatin A-4 (CA-4) wurde 1982 erstmals, gemeinsam mit 
verwandten Verbindungen aus einer afrikanischen Weidenart, Combretum caffrum, 
isoliert. Die Verbindung zeigt sehr starke antimitotische Wirkung gegen einige 
menschliche Krebszelllinien. CA-4 bindet an Tubulin an der Colchicin-Bindungsstelle 
und unterdrückt somit das Polymerisationsgleichgewicht der Mikrotubuli in der Zelle. 
Dieser Prozess führt zum Zell-Zyklus-Arrest beim Übergang von Meta- zur Anaphase 
und letztendlich zur Apoptose. 
CA-4 zeigt in lebenden Systemen zwei große Nachteile. Einerseits kommt es zur 
Isomerisierung der cis-Doppelbindung zum thermodynamisch stabileren trans-Isomer, 
welches keine biologische Aktivität zeigt, und andererseits ist der Naturstoff sehr 
schlecht wasserlöslich. Um diese beiden Nachteile zu umgehen wurden in den 
vergangenen Jahren unzählige Derivate synthetisiert mit dem Ziel die biologische 
Wirksamkeit im Vergleich zum Natrustoff zu erhöhen. 
Ziel dieser Arbeit war die Synthese von CA-4 Derivaten durch Modifikation der cis-
Doppelbindung. Die Einführung von Carbozyklen mit unterschiedlicher Ringgröße 
verhindert die cis-trans-Isomerisierung. 
 
Abbildung 1: CA-4 Derivate 
Die Synthese des Cyclopropan-Derivates über die Cyclopropanierung mit Diazomethan 
als Schlüsselschritt ist im Laufe dieser Diplomarbeit gelungen. Alle End- und 
Zwischenprodukte wurden in Kooperation mit dem Institut für Pharmakodynamik und 
Biopharmazie an der Universität Szeged an zwei verschiedenen Zelllinien (HeLa und 
MCF 7) auf ihre biologische Aktivität getestet. 
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